

Accepted Manuscript

Synthesis and Biological Evaluation of 6-Substituted-5-Fluorouridine ProTides.

Magdalena Slusarczyk, Salvatore Ferla, Andrea Brancale, Christopher McGuigan


PII: S0968-0896(17)31978-8
DOI: <https://doi.org/10.1016/j.bmc.2017.11.037>
Reference: BMC 14089

To appear in: *Bioorganic & Medicinal Chemistry*

Received Date: 10 October 2017
Revised Date: 21 November 2017
Accepted Date: 23 November 2017

Please cite this article as: Slusarczyk, M., Ferla, S., Brancale, A., McGuigan, C., Synthesis and Biological Evaluation of 6-Substituted-5-Fluorouridine ProTides., *Bioorganic & Medicinal Chemistry* (2017), doi: <https://doi.org/10.1016/j.bmc.2017.11.037>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Synthesis and Biological Evaluation of 6-Substituted-5-Fluorouridine ProTides.

Magdalena Slusarczyk^{*1}, Salvatore Ferla,¹ Andrea Brancale,¹ Christopher McGuigan¹

¹School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, King Edward VII Avenue, Cardiff CF10 3NB, UK.

^{*}Author for correspondence:

Tel.: +44 02920874551

SlusarczykM1@cardiff.ac.uk

In memory of, and dedicated to Professor Christopher McGuigan (1958-2016).

Abstract

A new family of thirteen phosphoramidate prodrugs (ProTides) of different 6-substituted-5-fluorouridine nucleoside analogues were synthesized and evaluated as potential anticancer agents. In addition, antiviral activity against Chikungunya (CHIKV) virus was evaluated using a cytopathic effect inhibition assay. Although a carboxypeptidase Y assay supported a putative mechanism of activation of ProTides built on 5-fluorouridine with such C6-modifications, the Hint docking studies revealed a compromised substrate-activity for the Hint phosphoramidase-type enzyme that is likely responsible for phosphoramidate bioactivation through P-N bond cleavage and free nucleoside 5'-monophosphate delivery. Our observations may support and explain to some extent the poor *in vitro* biological activity generally demonstrated by the series of 6-substituted-5-fluorouridine phosphoramidates (ProTides) and will be of guidance for the design of novel phosphoramidate prodrugs.

Keywords: Orotidine-5'-monophosphate decarboxylase (ODCase), nucleoside analogue (NA), phosphoramidate (ProTide) approach, anticancer, human Hint enzyme

Introduction

Antimetabolites such as nucleoside analogues (NAs) play a crucial role in the clinical treatment of patients with cancer and viral infections.¹⁻³ Nucleoside analogues

are chemically-modified synthetic compounds that have been developed with the aim to closely mimic their natural counterparts. Hence, they have a good chance to be able to be taken-up by cells, metabolized and incorporated into nucleic acids to subsequently inhibit cellular division and/or viral replication. At the molecular level, the biological effect of NAs is usually exerted following their metabolic conversion into corresponding 5'-mono-, di- and tri-phosphate forms. In addition to their incorporation into newly synthesized DNA or RNA, NAs can target and inhibit intracellular enzymes like for example viral or human polymerases, ribonucleotide reductase⁴ (RNR), thymidylate synthase⁵ (TS) or orotidine-5'-monophosphate decarboxylase^{6a,b} (ODCase). All these enzymes are involved either in the DNA or RNA synthesis, DNA repair or *de novo* pyrimidine nucleotide synthesis. Because *de novo* synthesis of pyrimidine nucleotides is upregulated during abnormal cell growth or during the replication of cells, when the demand for pyrimidine nucleotides is high, the ODCase can be considered as one of the potential anticancer targets.⁷ In fact, in the last decades a significant interest has been given to ODCase as a drug target for a number of modified nucleos(t)ide analogues, in particular C6-substituted UMP derivatives also in the antiviral and antimalarial arena.⁷⁻¹⁰ This is due to a pivotal role that ODCase plays in the *de novo* synthesis of pyrimidine nucleotides such as uridine-5'-*O*-monophosphate (UMP, **2**) from orotidine-5'-*O*-monophosphate (OMP, **1**, Figure 1) via decarboxylation^{6a} and its extraordinary reaction rate enhancement (over 17 orders of magnitude) in comparison with spontaneous uncatalyzed decarboxylation of OMP observed in water at neutral pH and ambient temperature.^{11a,b} Present in most species except viruses, ODCase exists as a monofunctional enzyme in bacteria and parasites and as a part of the bifunctional enzyme UMP synthase in human and other high-developed organisms.^{12a,b} A number of nucleoside-like and non-nucleoside ODCase inhibitors have been developed and reported in the literature¹³ with 6-azauridine^{14a-c} (**3**) and pyrazofurin¹⁵ (**4**) as representative examples of the nucleoside class of compounds being effective at the monophosphate level (Figure 2). In 2009, Kotra and co-workers reported in cell-based assays a variety of modified 5-fluorouridine (Figure 2) nucleoside derivatives bearing at the 6-position of the pyrimidine nucleobase small groups like iodo, azido, amino, or ethyl as potent anticancer agents, and their corresponding monophosphate analogues as inhibitors of human (*Hs*) and *Methanobacterium thermoautotrophicum* (*Mt*) ODCase.¹⁶ Later, the

same group disclosed novel N-modified cytidine-based (CMP) orotidine-5'-monophosphate decarboxylase inhibitors with anti-parasitic activity, improved inhibition of the catalytic enzyme activity and binding conformations studies.¹⁷




Figure 1. *De novo* synthetic pathway of OMP (1) to UMP (2) catalysed by ODCase.

Nucleoside analogues, including the above-mentioned 6-substituted-5-fluorouridines are biologically effective after being phosphorylated into their 5'-monophosphate and further to their 5'-di- and 5'-triphosphate forms. The effectiveness of NAs can be impaired as a consequence of limited cellular uptake via nucleoside-specific transporters, down-regulation of nucleoside kinases responsible for the phosphorylation step (activation) and up-regulation of deactivating enzymes (i.e nucleoside deaminases, purine/pyrimidine nucleoside phosphorylase...).¹⁸ To overcome these limitations, and thus improving their effectiveness, several prodrug approaches have been developed and reviewed over the last years. Notably, phosphate and phosphonate prodrugs such as phosphodiester (HepDirect, CycloSal, SATE) or phosphoramidates in which a nucleoside analogue is linked to the prodrug entity by either a phosphorus-oxygen or a phosphorus-nitrogen bond, respectively, have been extensively studied.¹⁹⁻²¹ One of the prominent strategies applied in the modulation of the activity of many nucleoside analogues and potentially overcoming the NA limitations accounting on both innate and acquired resistance of cancer cells to nucleoside analogues, is the ProTide technology pioneered by McGuigan and colleagues.²² Designed to mask the negative charges in a "monophosphate moiety" of a ProTide template, the ProTide approach introduces an amino acid ester and aryloxy entities as two lipophilic and biolabile groups linked to the phosphate part of the molecule. These two groups increase membrane permeability thereby circumventing the need for nucleoside-transporters and after their intracellular metabolism delivering a nucleoside monophosphate form suitable for further phosphorylation and exertion of its eventual biological activity.




Figure 2. Examples of anticancer nucleoside analogues (**3-11**) targeting different intracellular enzymes to exert their eventual biological activity.

The phosphoramidate (ProTide) technology has now an established position in the nucleotide prodrug field and led to the discovery of clinically successful drugs such as Sofosbuvir²³ (FDA approval in 2013 for the treatment of HCV, **12**) and others being subject of currently ongoing clinical trials as exemplified in Figure 3 for antiviral (i.e. stampidine²⁴ (phase I for HIV treatment, **13**), and anticancer (i.e. thymectacin)²⁵ (phase I/II, **14**), NUC-1031²⁶ (phase II, **15**) and NUC-3373²⁷ (phase I, **16**) activity. In our laboratory we have extensively investigated and applied the ProTide technology to a number of antiviral²⁸⁻³⁰ and anticancer agents such as for example 5-fluoro-2'-deoxyuridine (FdUrd),³¹ and gemcitabine.³² As part of our anticancer program and driven by our continuous interests in the discovery of novel anticancer agents we decided to apply the ProTide approach also to 6-substituted-5-fluorouridine analogues. In addition, a new class of 2'-fluoro-6-substituted uridine derivatives reported in the literature⁷ as potential inhibitors of ODCase revealed the lack of

cellular anticancer activities most likely due to their poor activation to the corresponding 5'-monophosphate forms. Herein, we report the ProTide technology approach employed to 6-substituted-5-fluorouridine analogues (**5-8**) to design novel nucleoside phosphoramidates (**25-37**) as potential anticancer agents. These compounds were prepared with the aim to improve cellular uptake of their parent nucleoside analogues and intracellular delivery of their corresponding monophosphate forms. All compounds were preliminary tested for their IC₅₀ activity in a panel of cancer cell lines including tumor cell lines of hematopoietic origin as these cell lines were found to be strongly inhibited by 6-substituted-5-fluorouridine analogues.¹⁶




Figure 3. Examples of antiviral and anticancer phosphoramidate-type prodrugs.


Chemistry

The 6-modified nucleosides **5-8** were prepared according to previously reported methods¹⁶ starting from a two-steps full protection of 5-fluorouridine (**17**) to give an intermediate (**19**) as shown in Scheme 1. The treatment of compound **19** with LDA followed by iodination with I₂ led to the formation of the key nucleoside **20** that was further deprotected under acidic conditions to yield 6-I-FUR (**5**). In addition the iodo-derivative **20** was used to form three other 6-substituted nucleoside analogues, such as 6-azido-, 6-methyl- and 6-ethyl-FUR (**21-23**). The 6-azido-derivative **21** was

prepared by treating **20** with NaN_3 followed by removal of its silyl and isopropylidene moieties to give compound **6**. The 6-methyl (**22**) and 6-ethyl (**23**) derivatives were successfully prepared using a modified procedure¹⁶ in one-pot reaction upon the treatment of **19** with LDA and subsequent addition of 2.0 eq. of CH_3I . Interestingly, both derivatives **22** and **23**, the latter compound obtained as a side product upon the additional methylation of monomethylated derivative **22**, were isolated and further submitted to the standard acidic deprotection conditions to furnish nucleosides **7** and **8**, respectively. Next, the ProTide technology was applied to the four nucleoside analogues **5-8** leading to the formation of 6-substituted-5-fluorouridine ProTides **25-37** in moderate yields. The key reagents used in the synthesis of ProTides are the arylaminoacyl phosphorochloridates represented by the general structure **24**, formed by allowing the aryl phosphorodichloridates, either phenyl or 1-naphthyl, to react with L-alanine esters in the presence of triethylamine at low temperature (Scheme 2). The formation of phosphorochloridates **24**, each obtained as a pair of diastereoisomers at the phosphate centre (1:1 mixture), was monitored and confirmed by ^{31}P NMR. Due to their limited stability, **24** were used in the ProTide syntheses as crude materials or after rapid silica gel chromatography. Finally, the four 6-modified nucleosides **5-8** were reacted with the key reagents **24** in the presence of NMI to give a number of ProTides **25-37** isolated as diastereoisomeric mixtures (4-17% yield), as evidenced by ^{31}P NMR, HPLC (two peaks), ^1H NMR, and ^{13}C NMR (splitting of many nucleoside signals). Given the low yield of ProTides formation and requirement for an extensive and repeated chromatographic purification, the final compounds **25-37** were submitted to *in vitro* evaluation as diastereoisomeric mixtures. Because a primary goal of the following study was to establish preliminary biological activity, at this stage a coupling reaction conditions and methods of isolation of final ProTides as two separate diastereoisomeres were not optimized in the present report.

Scheme 1. Synthesis of 6-substituted-5-fluorouridine nucleoside analogues **5-8**^a.

Scheme 2. General synthesis of 6-modified ProTides **25-37**^a.



Reagents and conditions: (a) for the synthesis of 1-naphthyl phosphorodichloridate POCl₃, Et₃N, anhydrous Et₂O, -78 °C for 1 h, then room temp for 1 h, 91%; phenyl phosphorodichloridate commercially available; (b) phenyl or 1-naphthyl phosphorodichloridate, Et₃N, anhydrous DCM, -78 °C for 1 h, then room temp for 1 – 3 h, 70-90%; (c) NMI, anhydrous THF, room temp, 16 h, 4-17%.




Figure 4. Four classes of 6-substituted-5-fluorouridine target ProTides (**25-37**).

Biology

The cytostatic activities of 6-substituted-FUR ProTides **25-37** (Figure 4) were evaluated against various cancer cell lines including human breast adenocarcinoma (MCF-7), colon (SW620), pancreatic (Mia-Pa-Ca), acute myeloid leukaemia (MV4-11), erythroleukaemia (HEL92.1.7), non-Hodgkin's lymphoma (RL) and Hodgkin's lymphoma (HS445). The L-alanine-Bn-Naph 6-I-FUR prodrug **27** was among the most active in the series of all 6-modified-FUR ProTides with submicromolar IC₅₀ values ranging between 0.08 μ M (MV4-11) and 3.9 μ M in (MCF-7) cell cultures. The ProTide **27** proved to be equipotent as a cytostatic agent as its parent nucleoside **5** in SW620 cell cultures (0.52 vs 0.50 μ M) and 1.8–5.8-fold less potent against HS445 (0.71 vs 0.38 μ M) and MCF-7 cell cultures (3.9 vs 0.67 μ M), respectively. The loss of

inhibitory activity of the prodrug *versus* **5** was more significant for two other L-alanine 6-I-FUR ProTides, the phenyl-pentyl **25** and phenyl-cyclohexyl **26**, and the activity loss ranged between 2–65-fold and 9–228-fold, respectively.

In the 6-N₃-FUR series, the cytostatic activities for nucleoside analogue **6** were in the lower micromolar range (6–14 μ M), whereas for three 6-N₃-FUR ProTides (**30**, **31**, **32**) the IC₅₀ values ranged between 6.0 and 44 μ M. The ProTides **31** and **32** turned out to be relatively equipotent in three cell lines of hematopoietic origin (MV4-11, RL and HS445) with a 2.3-fold boost in activity for **31** *versus* the parent nucleoside **6** (6.0 μ M vs 14.0 μ M in the HS445 cell line). In general, the solid tumour cell lines were markedly less sensitive to the 6-N₃-FUR ProTides in particular to the L-alanine phenyl hexyl (**29**) and phenyl ethyl (**28**) derivatives with the latter compound even being inactive up to 50 μ M in six out of seven cancer cell lines.

Similar to nucleoside **6**, the 6-Me-FUR nucleoside **7** exerted micromolar activity across all tumor cell lines tested ranging between 2.0 μ M (MV4-11) and 16 μ M (RL). In the 6-Me-FUR series, no cytostatic activity was detected for ProTides **33–36** up to 50 μ M in the panel of cancer cell lines. A somewhat similar trend was noted for 6-Et-FUR (**8**) *versus* its ProTide derivative **37**, although the latter compound showed micromolar activity in three out of five tumour cell lines (IC₅₀'s for SW620 10 μ M; for RL 27 μ M; and for HS445 10 μ M).

Table 1. Cytotoxicity of 6-modified-FUR ProTides **25–37** reported as "IC₅₀ (μ M) Values.

Comp	Nucleoside	AA	Ester (R)	IC ₅₀ (μM)							
				Cell lines							
				Aryl	MCF-7	SW620	Mia-Pa-Ca	MV4-11	HEL92.1.7	RL	HS445
6-I-FUR	5	-	-	-	0.67	0.50	0.02	0.04	0.1	0.1	0.38
25	5	L-Ala	Pnt	Ph	7.83	1.12	1.31	0.20	0.5	0.8	2.6
26	5	L-Ala	cHex	Ph	8.12	4.84	4.57	0.74	4.1	2.6	3.8
27	5	L-Ala	Bn	Naph	3.93	0.52	0.63	0.08	0.4	0.4	0.71
6-N ₃ -FUR	6	-	-	-	6	8	11	6.6	10	10	14
28	6	L-Ala	Et	Ph	>50	>50	>50	>50	>50	>50	44
29	6	L-Ala	Hex	Ph	>50	38	>50	9.0	39	20	18
30	6	L-Ala	Bn	Ph	20	13	22	8.0	17	21	23
31	6	L-Ala	Hex	Naph	31	21	24	6.2	10	9.0	6.0
32	6	L-Ala	Bn	Naph	44	28	27	6.3	29	12	15
6-Me-FUR	7	-	-	-	5.4	8.5	12	2.0	14	16	7.0
33	7	L-Ala	Hexyl	Ph	>50	>50	>50	>50	>50	>50	>50
34	7	L-Ala	Bn	Ph	>50	>50	>50	>50	>50	>50	>50
35	7	L-Ala	neoPnt	Naph	>50	>50	>50	>50	>50	>50	>50
36	7	L-Ala	Bn	Naph	>50	>50	>50	>50	>50	>50	>50
6-Et-FUR	8	-	-	-	>50	>50	ND	ND	>50	>50	>50
37	8	L-Ala	Bn	Naph	>50	12	ND	ND	>50	27	10

Cytotoxicity data reported as "IC₅₀ (μM) values (50% inhibitory concentration of cell viability). The compounds were added to the cell in duplicate and tested in 9 serial concentrations from 198 μM to 0.0199 μM.

The screening of the compounds was performed on a broad variety of at least 6 different cancer cell lines to cover different metabolic properties that may exist between different types of cancer cells that may result in a different outcome of the eventual cytostatic activity of the compounds. In fact, it was observed that the cytostatic activity for some of the 6-substituted-FUR derivatives and their corresponding prodrugs (i.e. 6-I-FUR, 6-Me-FUR) may significantly differ depending on the nature of the prodrug part in the molecule and/or the nature of the tumor cell line investigated. Although the molecular basis of the observed differences are not further investigated in detail yet, the cytostatic differences may be most likely due to i) differences in drug uptake (i.e. depending on the presence and activity of different nucleoside carriers in the tumor cell membrane) and/or efflux of the drugs by the different tumor cell lines, ii) differences in levels and activity of metabolic enzymes that intracellularly convert the particular nucleotide prodrug to the parent nucleotide

5'-monophosphate, and/or iii) differences in nucleotide kinases and other enzymes that may convert the nucleoside 5'-monophosphate to the eventual 5'-triphosphate (i.e. nucleoside 5'-monophosphate kinases and nucleoside 5'-diphosphate kinases) or to the free nucleoside or nucleobase (i.e. 5'-nucleotidases, thymidine phosphorylase). Thus, a complex interplay of a broad variety of enzymes in the particular tumor cell lines will play a determining role in the eventual cytostatic activity of the nucleotide prodrugs. It would therefore be of importance to identify these different factors to clarify and understand the underlying metabolic processes that lead to the cytostatic activity of the different ProTides.

Moreover, it has been suggested that anticancer activity of 6-substituted-FUR analogues might be exerted via inhibition of thymidylate synthase (TS). These 6-modified nucleosides would be intracellularly degraded to their nucleic bases by thymidine phosphorylase (TPase) and further transformed to the corresponding 2'-deoxynucleosides as acceptable substrates for TS.¹⁶ In the studies of 5-fluoro-2'-deoxyuridine (FdUrd) ProTides, we have previously reported that FdUrd ProTides are completely stable in the presence of TP and uridine phosphorylase (UP).³³ In this view, it might be speculated that the ProTide promoiety introduced into the 6-substituted-5-fluorouridine analogues can potentially compromise activity of such compounds as it would prevent their conversion to 6-substituted-5-fluorouracil. Thus, a formation of 6-substituted-2'-deoxy-5-fluorouridine derivatives and their corresponding monophosphate forms would be impaired resulting in potential lack of TS inhibition.

Antiviral Activity *In vitro*

ODCase has been considered as a potential target for agents directed against RNA viruses such as flaviviruses, and togaviruses.³⁴ Numerous pyrimidine-nucleosides and their derivatives including the phosphoramidate prodrug 6-aza-uridine-5'-(ethyl-methoxyalaninyl)phosphate were shown to exhibit antiviral (RNA) activity *in vitro* and *in vivo*.^{14c} In addition, 6-azauridine was also reported as an *in vitro* inhibitor of Chikungunya virus (CHIKV) via inhibition of host ODCase rather than by inhibiting viral specific enzymes.^{35a,b} CHIKV as a re-emerging RNA virus for which currently there is no approved treatment or vaccination,³⁶ is considered as a global health concern. Although, the recent expanding knowledge about the CHIKV genome allows

design of inhibitors that would target individual viral enzymes,^{37a-c} there is continuous need for the discovery of novel anti-CHIKV agents. In this view, we evaluated selected nucleosides (**6**, **7**) and their ProTides **32**, **33**, **35-37** against Chikungunya virus in cell culture. Most of the compounds tested in the cytopathicity (CPE)-based assay were devoid of antiviral activity (EC_{50} of $>200 \mu\text{M}$ in comparison with the control 6-azauridine $EC_{50} = 0.468 \mu\text{M}$). However, five compounds (**6**, **32**, **7**, **35** and **37**) proved to be cytotoxic in a CC_{50} range of $9.4\text{-}82 \mu\text{M}$. A significant difference in cytotoxicity was observed for the 6-alkylated nucleoside analogues 6-methyl-FUR (**7**, $9.0 \mu\text{M}$) *versus* 6-ethyl-FUR (**8**, $>200 \mu\text{M}$) as well as their corresponding ProTides, in particular **36** ($>200 \mu\text{M}$) and **37** ($53 \mu\text{M}$), respectively.

Table 2. Antiviral activity and cytotoxicity in Vero cells of nucleosides **6**, **7** and **8** and ProTides **32**, **33**, **35-37**.

Comp	Nucleoside	AA	Ester (R)	Aryl	EC_{50} (μM)	CC_{50} (μM)
6-N ₃ -FUR	6	-	-	-	>200	47.02
32	6	L-Ala	Bn	Naph	>200	81.80
6-Me-FUR	7	-	-	-	>200	9.04
33	7	L-Ala	Hexyl	Ph	>200	>200
35	7	L-Ala	neoPnt	Naph	>200	81.29
36	7	L-Ala	Bn	Naph	>200	>200
6-Et-FUR	8	-	-	-	>200	>200
37	8	L-Ala	Bn	Naph	>50	53.10
6-Azauridine	3	-	-	-	0.468	>10

EC_{50} or compound concentration required to inhibit the Chikungunya virus-induced cytopathic effect of 50%. The compounds were added to the cells in triplicate and tested in 6 serial concentrations from $198 \mu\text{M}$ to $0.0196 \mu\text{M}$.

Prodrugs such as phosphoramidates exert their biological activity after metabolic activation³⁸ and intracellular release of the monophosphate form, which would next be phosphorylated to their di- and -triphosphates. In general, the first step in the activation pathway for ProTides is believed to be a hydrolysis of an ester moiety in the amino acid part of the prodrug to form the intermediate **29-A** (Scheme 3). This step is mediated by a carboxyesterase-type enzyme and is followed by a spontaneous cyclization leading to a displacement of an aryl moiety *via* an internal nucleophilic attack of the carboxylate residue on the phosphorus to yield an unstable cyclic intermediate **29-B**. In the following two final steps, the cyclic anhydride **29-B** is hydrolyzed to the intermediate **29-C**, which further give rise to the corresponding monophosphate **29-D** upon P-N bond cleavage mediated by the phosphoramidase-type enzyme.³⁹ In order to assess whether also 6-substituted-FUR ProTides act as a good substrate for the carboxyesterase-type enzyme and hence would be activated by the same common pathway, we performed the carboxypeptidase Y assay on one of the 6-N₃-FUR ProTide, the compound **29** using a reported assay procedure.⁴⁰ Thus, compound **29** dissolved in acetone-*d*₆ in the presence of Trizma buffer (pH 7.6) was treated with carboxypeptidase Y and submitted to ³¹P NMR analysis over 14 h (Figure 5). Two peaks recorded in the blank spectrum at δ_p 3.64 and 3.82 ppm, correlate to the diastereoisomers of the parent ProTide **29**. Within the first 10 min of the experiment the prodrug **29** was rapidly hydrolysed to the first metabolite **29-A**, lacking the ester moiety (represented as two signals at δ_p 4.68 and 4.87 ppm), which further was processed to the corresponding metabolite **29-C** (single peak at δ_p 7.17 ppm). A complete conversion of the ProTide **29** to **29-C** occurred within approximately 60 min with an estimated half-life of less than 5 min.

Scheme 3. Proposed Activation Route of 6-N₃-FUR ProTide **29**.




Figure 5. Carboxypeptidase Y-mediated cleavage of ProTide **29** as monitored by ³¹P NMR.

Docking Studies: Human Hint Enzyme

The last enzymatic step required for the activation of phosphoramidate prodrugs is the cleavage of the P-N bond catalysed by the phosphoramidase-type enzyme, which belongs to the human histidine triad nucleotide-binding protein (Hint).⁴¹ The efficiency of this step determines the eventual activity of ProTides since during this step the free nucleoside monophosphate form is intracellularly delivered. In order to investigate the potential interaction between Hint protein and metabolite **29-C** and to assess its potentiality as a substrate of this enzyme, a series of molecular docking studies using the human Hint enzyme (PDB id: 1KPF)⁴² were performed. The catalytic active-site is well-defined by the co-crystallized adenosine monophosphate (AMP), with the three histidine residues interacting with the substrate and Ser107, an important amino acid reported as playing a central role in catalysing the P-N bond cleavage through an acid-base catalysis,⁴³ making an interaction with the phosphate head. Figure 6 shows the metabolite **29-C** proposed binding mode into the Hint enzyme active pocket. The nucleobase and the sugar are oriented in a different manner if compared to the AMP substrate thus forcing the phosphate moiety in a not-ideal position for the cleavage of the P-N bond (lacking direct interaction with Ser107). This results in a binding that could be considered as being not optimal for the proper enzyme catalytic activity. The docking results seem to suggest that **29-C** and, as a consequence, the other members of this new ProTide series, might not be optimal substrates for Hint. Therefore, the release of the monophosphate form could be drastically reduced or even completely impeded. These findings are in line with previously reported data in which the Hint enzyme has been found to have a lower affinity for pyrimidine than purine derivatives^{43,44} and could potentially explain the substantial reduction or even the total lack of cytostatic activity of 6-substituted-FUR ProTides in general when compared with the parent nucleoside.




Figure 6. Proposed binding mode of metabolite **29-C** (carbon atoms in orange) in the Hint-1 enzyme. The nucleobase and the sugar occupy the binding site in a different manner when compared with AMP (carbon atoms in green), forcing the P-N bond away from the catalytic Ser107.

Conclusion

In conclusion, we report on the application of the ProTide approach to 6-substituted-5-fluorouridine nucleoside analogues bearing at the C6-position of the 5-fluorouridine scaffold small substituents such as iodo, azido, methyl and ethyl with the aim to prepare potential anticancer and anti-viral agents. It is worth mentioning that during the one-pot synthesis of the 6-alkyl substituted-5-fluorouridine analogues using methyl iodide and LDA, two derivatives were formed and isolated, being the target 6-methyl- and 6-ethyl-5-fluorouridine (as a side-product), respectively. In general, in our *in vitro* studies, 6-substituted-5-fluorouridine ProTides revealed to be less active in comparison with the parent nucleosides. Among four different 6-substituted-5-fluorouridine ProTide series, only the 6-iodo- (**27**) and 6-azido- (**31** and **32**) compounds were equipotent to the parent nucleosides **5** and **6**. The differences in and/or lack of anticancer and anti-CHIKV activity in most cases may indicate either differences in drug uptake depending on the tumor cell, differences in levels and activity of metabolic enzymes and/or poor bioactivation and thus inefficient delivery of a free nucleoside 5'-monophosphate form, respectively. Although carboxypeptidase

Y was able to efficiently activate these phosphoramidate prodrugs to their nucleoside aminoacid phosphate key metabolite, the ProTides seem to be poor, if any substrate for the Hint enzyme. The HINT docking studies performed with 6-azido-fluorouridine metabolite indeed showed that structures bearing modifications at the C6-position in a nucleobase moiety are not recognized as good substrates for the phosphoramidase-type Hint enzyme. Overall, the application of the phosphoramidate approach to 6-substituted-5-fluorouridine nucleosides was only modestly successful since none of the ProTides tested showed a significant boost in cytostatic activity against a broad panel of cancer cell lines in comparison with the parent nucleoside analogues. These finding should be kept in mind for the design of novel phosphoramidate ProTides.

Experimental Section

MTS Cell Viability Assay. The assay was contracted and carried-out by WuXi AppTec (Shanghai) Co., Ltd. The tumour cell lines MCF-7, SW620, Mia-Pa-Ca, MV4-11, HEL92.1.7, RL and HS445 were seeded at cell densities of 0.5 to 100 x 10³ cells/well in a 96-well plate the day before drug incubation. Then the plates were incubated for 72 hours with the different concentrations of compound to be tested. After the incubation period, 50 µL of MTS was added and the tumour cells were incubated for 4 h at 37 °C. The data were read and collected by a Spectra Max 340 Absorbance Microplate Reader. The compounds were tested in duplicate with 9 serial concentrations (3.16-fold titrations with 198 µM as the highest concentration), and the data were analyzed by XL-fit software.

Chikungunya CPE-based EC₅₀ Assay. The assay was contracted and carried-out by IBT Bioservices. Vero cells were seeded in 96-well plates and incubated overnight. The next day 6 serial dilutions (starting at 198 µM with 6.32-fold dilutions) of the test compounds and a control compound (6-azauridine) were prepared in culture medium. The growth medium was aspirated from the cells and the compound dilutions were added to the cells in triplicate for a one-hour incubation period. Thereafter, the virus was added at a predetermined MOI (0.01) and the cells were incubated for 3 days. The cell cultures were then fixed and stained with crystal violet in glutaric dialdehyde solution. The optical density was determined and the EC₅₀'s were calculated using the uninfected (cell only) control as 0% CPE and the controls without compound (virus only) as 100% CPE using a 4-PL curve fit of the OD.

Cytotoxicity Assay. The assay was contracted and carried-out by IBT Bioservices. Vero cells were seeded in 96-well plates and incubated overnight. The next day serial dilutions of the test compounds and a control compound (6-azauridine) were prepared. The growth medium was aspirated from the cells and the compound dilutions were added in triplicate. Cells that were incubated with medium only were used for generating the 0% cytotoxicity data. Medium was aspirated and cells were lysed for evaluation of the ATP content using Promega's CelltiterGlo kit on day 3. The resulting luciferase luminescence was quantified and used to calculate the CC₅₀ using a 4-PL curve fit of the OD.

Carboxypeptidase Y (EC 3.4.16.1) Assay. The experiment was carried-out by dissolving ProTide **29** (5.0 mg) in acetone-*d*₆ (0.15 mL) followed by addition of 0.30 mL of Trizma buffer (pH 7.6). After recording the control ³¹P NMR at 25 °C, a previously defrosted carboxypeptidase Y (0.1 mg dissolved in 0.15 mL of Trizma) was added to the sample, which was then immediately submitted to the ³¹P NMR analyses (at 25 °C). The spectra were recorded every 7 minutes and followed 14 hours. ³¹P NMR recorded data were processed and analyzed with the Bruker Topspin 2.1 program.

Chemistry. General Procedures. Solvents and Reagents. The following anhydrous solvents were purchased from Sigma-Aldrich: dichloromethane (CH₂Cl₂), diethyl ether (Et₂O), tetrahydrofuran (THF), dimethylformamide (DMF), and any other reagents used. Amino acid esters commercially available were purchased from Novabiochem. All reagents commercially available were used without further purification.

Thin Layer Chromatography (TLC).

Precoated aluminum backed plates (60 F254, 0.2 mm thickness, Merck) were visualized under both short- and long-wave ultraviolet light (254 and 366 nm). Preparative TLC plates (20 cm × 20 cm, 500-2000 μm) were purchased from Merck.

Flash Column Chromatography. Flash column chromatography was carried-out using silica gel supplied by Fisher (60A, 35-70 μm). Glass columns were slurry-packed using the appropriate eluent with the sample being loaded as a concentrated solution in the same eluent or preadsorbed onto silica gel. Fractions containing the product were identified by TLC, pooled and the solvent was removed *in vacuo*.

High Performance Liquid Chromatography (HPLC). The purity of the final compounds was verified to be >95% by HPLC analysis using either i) ThermoSCIENTIFIC, SPECTRA SYSTEM P4000, detector SPECTRA SYSTEM UV2000, Varian Pursuit XRs 5 C18, 150 x 4.6 mm (as an analytical column) or ii) Varian Prostar (LC Workstation-Varian Prostar 335 LC detector), Thermo SCIENTIFIC Hypersil Gold C18, 5 μ m, 150 x 4.6 mm (as an analytical column). For the method of elution, see the experimental part.

Nuclear Magnetic Resonance (NMR). ^1H NMR (500 MHz), ^{13}C NMR (125 MHz), ^{31}P NMR (202 MHz) and ^{19}F NMR (470 MHz) were recorded on a Bruker Avance 500 MHz spectrometer at 25 °C. Chemical shifts (δ) are quoted in parts per million (ppm) relative to internal $\text{MeOH-}d_4$ (δ 3.34 ^1H -NMR, δ 49.86 ^{13}C -NMR) and CHCl_3 - d_4 (δ 7.26 ^1H NMR, δ 77.36 ^{13}C NMR) or external 85 % H_3PO_4 (δ 0.00 ^{31}P NMR). Coupling constants (J) are measured in Hertz. The following abbreviations are used in the assignment of the NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad singlet), dd (doublet of doublet), dt (doublet of triplet), app (apparent). The assignment of the signals in ^1H NMR and ^{13}C NMR was done based on the analysis of coupling constants and additional two-dimensional experiments (COSY, HSQC, HMBC, PENDANT).

Mass spectrometry (MS). Low resolution mass spectra were performed on Bruker Daltonics microTof-LC, (atmospheric pressure ionization, electron spray mass spectroscopy) in either positive or negative mode.

Purity of final compounds. The $\geq 95\%$ purity of all the final compounds was confirmed using HPLC analysis.

The following compounds 2',3'-*O*-isopropylidene-5-fluoro-uridine (**18**), 5'-*O*-(*t*-butyldimethylsilyl)-2',3'-*O*-isopropylidene-5-fluoro-uridine (**19**), fully protected 6-substituted nucleosides **20-23** and their deprotected analogues **5-8** were prepared according to the slightly modified procedures previously reported in the literature and the experimental data are in agreement with the data reported.¹⁶

5'-*O*-(*t*-Butyldimethylsilyl)-2',3'-*O*-isopropylidene-5-fluoro-uridine (19**).** To a stirred suspension of 5-fluorouridine (3.0 g, 11.4 mmol) in anhydrous acetone (120 mL) H_2SO_4 (1.5 mL) was added dropwise at 0°C. The reaction mixture was stirred for 2 h at room temperature. The mixture was then neutralized with 6N NH_4OH and

evaporated to afford crude product which was purified by column chromatography with gradient of MeOH in DCM (5 to 8%) to yield 2',3'-*O*-isopropylidene-5-fluorouridine (**18**) as a white solid (3.30 g, 96%). ¹H NMR (500 MHz, MeOD): δ 8.18 (1H, d, $J = 7.0$ Hz, *H*-6), 5.92 (1H, d, $J = 2.5$ Hz, *H*-1'), 4.89 (1H, dd, $J = 6.5, 2.5$ Hz, *H*-2'), 4.87 – 4.85 (1H, apparent m, *H*-3'), 4.25 (1H, apparent q, $J = 3.0$ Hz *H*-4') 3.83 (1H, dd, $J = 12.0, 3.0$ Hz, 1 x *H*-5'), 3.75 (1H, dd, $J = 12.0, 3.0$ Hz, 1 x *H*-5'), 1.56 (3H, s, CH₃), 1.37 (3H, s, CH₃). A solution of **18** (3.30 g, 10.91 mmol) in anhydrous DCM (130 mL) was treated with imidazole (1.48 g, 21.83 mmol), and TBDMSCl (1.64 g, 10.91 mmol) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 3 h. After solvent evaporation, the crude residue was re-dissolved in EtOAc (60 mL), washed with water (30 mL), brine (30 mL), and dried with Na₂SO₄. Evaporation of the solvent followed by purification by column chromatography with EtOAc/Hexane (3:7) gave 5'-*O*-(*t*-butyldimethylsilyl)-2',3'-*O*-isopropylidene-5-fluoro-uridine as a foam (4.08 g, 90%). ¹H NMR (500 MHz, CDCl₃): δ 7.99 (1H, d, $J = 7.0$ Hz, *H*-6), 5.87 (1H, d, $J = 1.5$ Hz, *H*-1'), 4.84 – 4.79 (2H, m, *H*-2', *H*-3'), 4.36 (1H, apparent q, $J = 3.0$ Hz *H*-4'), 3.98 (1H, d, $J = 11.5, 3.0$ Hz, 1 x *H*-5'), 3.87 (1H, d, $J = 11.5, 3.0$ Hz, 1 x *H*-5'), 1.56 (3H, s, CH₃), 1.37 (3H, s, CH₃), 0.94 (s, 9H, C(CH₃)₃), 0.14 (6H, s, Si(CH₃)₂); ¹³C NMR (125 MHz, MeOD): δ 158.27 (d, ² $J_{C-F} = 23.5$ Hz, *C*-4), 149.40 (*C*-2), 140.30 (d, ¹ $J_{C-F} = 231.0$ Hz, *C*-5), 125.31 (d, ² $J_{C-F} = 34.5$ Hz, *C*-6), 113.45 (C(CH₃)₃), 91.81 (*C*-1'), 87.23 (*C*-4'), 85.17 (*C*-2'), 80.72 (*C*-3'), 63.27 (*C*-5'), 26.08 (CH₃), 24.96 (C(CH₃)₃), 24.07 (CH₃), -6.81 (Si(CH₃)₂).

5'-*O*-(*t*-Butyldimethylsilyl)-2',3'-*O*-isopropylidene-5-fluoro-6-iodouridine (20**).** 5'-*O*-(*t*-Butyldimethylsilyl)-2',3'-*O*-isopropylidene-5-fluoro-uridine **19** (3.1 g, 7.44 mmol) was dissolved in anhydrous THF (40 mL) and at -78 °C was treated with dropwise addition of LDA (11.16 mL, 22.32 mmol, 2.0 M solution in THF). After stirring for 1 h, iodine (2.83 g, 11.2 mmol) dissolved in anhydrous THF (50 mL) was added slowly at -78 °C and the resulting mixture was stirred for an additional 6 h in dark. The reaction was quenched with water and brought to room temperature and diluted with EtOAc (80 mL). The organic layer was washed with water (40 mL), brine (40 mL), and dried over Na₂SO₄. The solvent was evaporated and further purified by column chromatography using EtOAc/Hexane (3:7) as an eluent to afford the product as a yellow foam (2.17 g, 54%). ¹H NMR (500 MHz, CDCl₃): δ 8.87

(1H, bs, NH), 6.10 (1H, d, $J = 1.5$ Hz, $H-1'$), 5.22 (1H, dd, $J = 6.5, 1.5$ Hz, $H-2'$), 4.83 (1H, dd, $J = 6.0, 4.0$ Hz, $H-3'$), 4.21 – 4.18 (1H, m, $H-4'$) 3.84 – 3.77 (2H, m, 2 x $H-5'$), 1.58 (3H, s, CH_3), 1.37 (3H, s, CH_3), 0.90 (s, 9H, $C(CH_3)_3$), 0.07 (6H, s, $Si(CH_3)_2$).

5-Fluoro-6-Iodouridine (5) A stirred solution of 5'-*O*-(*t*-butyldimethylsilyl)-2',3'-*O*-isopropylidene-5-fluoro-6-iodouridine **20** (2.0 g, 3.68 mmol) in water (6 mL) was treated with 50% aqueous (6 mL) at 0°C, brought to room temperature, and stirred for an additional 2 h in dark. The reaction mixture was concentrated under vacuum and was purified by column chromatography with a gradient of MeOH in DCM (5% to 10%) to give a product as a yellowish solid (1.24 g, 87%). 1H NMR (500 MHz, MeOD): δ 5.96 (1H, d, $J = 3.5$ Hz, $H-1'$), 4.76 (1H, dd, $J = 6.5, 3.5$ Hz, $H-2'$), 4.36 (1H, t, $J = 6.5$ Hz, $H-3'$), 3.92 (1H, td, $J = 6.0, 3.0$ Hz, $H-4'$) 3.83 (1H, dd, $J = 12.0, 3.0$ Hz, 1 x $H-5'$), 3.70 (1H, dd, $J = 12.0, 6.0$ Hz, 1 x $H-5'$); ^{13}C NMR (125 MHz, MeOD): δ_C 156.05 (d, $^2J_{C-F} = 29.0$ Hz, C-4), 148.74 (C-2), 145.29 (d, $^1J_{C-F} = 228.0$ Hz, C-5), 105.17 (d, $^2J_{C-F} = 39.0$ Hz, C-6), 103.16 (C-1'), 86.29 (C-4'), 73.42 (C-2'), 71.32 (C-3'), 63.71 (C-5'); MS (ES+) m/z : 387.96 ($M + Na^+$, 100%), Accurate mass: $C_9H_{10}FIN_2O_6$ required 387.96 found 410 ($M + Na^+$).

5'-*O*-(*t*-Butyldimethylsilyl)-2',3'-*O*-isopropylidene-5-fluoro-6-azidouridine (21).

The compound **20** (1.86 g, 3.43 mmol) dissolved in anhydrous DMF (15 mL) was treated with NaN_3 (0.22 g, 3.43 mmol). The reaction mixture was stirred for 3 h in dark. After that time, the solvent was evaporated, and the residue was re-dissolved in EtOAc (30 mL), washed with brine, and dried over Na_2SO_4 . The combined organic layers were evaporated and to afford a yellowish residue which was purified by column chromatography using DCM/MeOH (99:1) as an eluent to give compound **2** as a light-yellow solid (1.16 g, 74%). 1H NMR (500 MHz, $CDCl_3$): δ 9.40 (1H, s, NH), 6.08 (1H, d, $J = 1.5$ Hz, $H-1'$), 5.15 (1H, dd, $J = 6.5, 1.5$ Hz, $H-2'$), 4.80 (1H, dd, $J = 6.5, 4.5$ Hz, $H-3'$), 4.16 – 4.12 (1H, m, $H-4'$), 3.84 – 3.77 (2H, m, 2 x $H-5'$), 1.56 (3H, s, CH_3), 1.35 (3H, s, CH_3), 0.90 (s, 9H, $C(CH_3)_3$), 0.07 (6H, s, $Si(CH_3)_2$). MS (ES+) m/z : 480.2 ($M + Na^+$, 20%), Accurate mass: $C_{18}H_{28}FN_5O_6Si$ required 457.52 found 480.2 ($M + Na^+$), 937.4 (2 x $M + Na^+$).

5-Fluoro-6-azidouridine (6) A stirred solution of 5'-*O*-(*t*-butyldimethylsilyl)-2',3'-*O*-isopropylidene-5-fluoro-6-azidouridine **21** (1.10 g, 2.18 mmol) in water (10 mL) was treated with 50% aqueous (10 mL) at 0°C, brought to room temperature, and stirred

for an additional 2 h in dark. The reaction mixture was concentrated under vacuum and was purified by column chromatography with a gradient of MeOH in DCM (6% to 12%) to give a product as a yellowish solid (0.56 g, 85%). ^1H NMR (500 MHz, MeOD): δ 5.95 (1H, d, $J = 3.5$ Hz, $H-1'$), 4.65 (1H, dd, $J = 6.5, 3.5$ Hz, $H-2'$), 4.32 (1H, t, $J = 6.5$ Hz, $H-3'$), 3.86 – 3.81 (2H, m, $H-4'$, 1 x $H-5'$), 3.70 – 3.67 (1H, m, 1 x $H-5'$); ^{13}C NMR (125 MHz, MeOD): δ_{C} 156.54 (d, $^2J_{\text{C-F}} = 26.0$ Hz, C-4), 148.40 (C-2), 137.20 (d, $^1J_{\text{C-F}} = 213.0$ Hz, C-5), 132.8 (d, $^2J_{\text{C-F}} = 24.0$ Hz, C-6), 91.60 (C-1'), 86.29 (C-4'), 84.50 (C-2'), 71.94 (C-3'), 69.0 (C-5'); MS (ES+) m/z : 326.20 ($\text{M} + \text{Na}^+$, 100%), Accurate mass: $\text{C}_9\text{H}_{10}\text{FN}_5\text{O}_6$ required 303.06 found 326.20 ($\text{M} + \text{Na}^+$).

5'-O-(*t*-Butyldimethylsilyl)-2',3'-O-isopropylidene-5-fluoro-6-methyluridine (22)

and 5'-O-(*t*-Butyldimethylsilyl)-2',3'-O-isopropylidene-5-fluoro-6-ethyluridine (23).

5'-O-(*t*-Butyldimethylsilyl)-2',3'-O-isopropylidene-5-fluoro-uridine **19** (3.5 g, 8.40 mmol) was dissolved in anhydrous THF (40 mL) and at -78°C was treated with dropwise addition of LDA (12.6 mL, 25.20 mmol, 2.0 M solution in THF). After stirring for 1 h, CH_3I (1.04 mL, 16.80 mmol) dissolved in anhydrous THF (5 mL) was added and, and the mixture was stirred for 5 h at -78°C . The reaction was quenched with water (7 mL) and allowed to warm to rt and then dissolved in ethyl acetate (100 mL). The organic layer was washed with water (40 mL), brine (40 mL), and dried over NaSO_4 . The solvent was evaporated and the residue was purified by column chromatography using hexane/EtOAc (7:3) as an eluent to give the product **23** (fast eluting fraction, 0.75 g, 20%), and the product **22** (slow eluting fraction, 1.53 g, 42%), both as a white foam. ^1H NMR (500 MHz, CDCl_3): δ 10.40 (1H, s, NH), 5.63 (1H, d, $J = 1.0$ Hz, $H-1'$), 5.18 (1H, dd, $J = 6.0, 1.0$ Hz, $H-2'$), 4.78 (1H, dd, $J = 6.0, 4.5$ Hz, $H-3'$), 4.13 – 4.10 (1H, m, $H-4'$), 3.80 – 3.74 (2H, m, 2 x $H-5'$), 2.31 (3H, d, $J_{\text{H-F}} = 3.5$ Hz, C-6- CH_3), 1.50 (3H, s, CH_3), 1.30 (3H, s, CH_3), 0.83 (s, 9H, $\text{C}(\text{CH}_3)_3$), 0.02 (6H, s, $\text{Si}(\text{CH}_3)_2$). ^{13}C NMR (125 MHz, CDCl_3): δ_{C} 156.70 (d, $^2J_{\text{C-F}} = 28.0$ Hz, C-4), 149.20 (C-2), 138.40 (d, $^1J_{\text{C-F}} = 228.0$ Hz, C-5), 137.85 (d, $^2J_{\text{C-F}} = 24.3$ Hz, C-6), 113.78 ($\text{C}(\text{CH}_3)_3$), 91.89 (C-1'), 89.58 (C-4'), 84.12 (C-2'), 81.70 (C-3'), 64.10 (C-5'), 27.20 (CH_3), 25.87 ($\text{C}(\text{CH}_3)_3$), 25.31 (CH_3), 11.92 (d, $J_{\text{C-F}} = 2.9$ Hz, C-6- CH_3), -5.31 ($\text{Si}(\text{CH}_3)_2$).

5'-O-(*t*-Butyldimethylsilyl)-2',3'-O-isopropylidene-5-fluoro-6-ethyluridine (23). δ 9.70 (1H, s, NH), 5.57 (1H, d, $J = 1.5$ Hz, $H-1'$), 5.16 (1H, dd, $J = 6.5, 1.5$ Hz, $H-2'$), 4.77 (1H, dd, $J = 6.5, 4.5$ Hz, $H-3'$), 4.14 – 4.10 (1H, m, $H-4'$), 3.81 – 3.75 (2H, m, 2

x *H*-5'), 2.82 – 2.65 (2H, m, C-6-CH₂CH₃), 1.51 (3H, s, CH₃), 1.30 (3H, s, CH₃), 1.27 (3H, t, *J* = 8.0 Hz, C-6-CH₂CH₃), 0.83 (9H, s, C(CH₃)₃), 0.04 (6H, s, Si(CH₃)₂); ¹³C NMR (125 MHz, CDCl₃): δ_C 156.90 (d, ²*J*_{C-F} = 27.8 Hz, C-4), 149.28 (C-2), 143.00 (d, ²*J*_{C-F} = 23.9 Hz, C-6), 137.64 (d, ¹*J*_{C-F} = 229.3 Hz, C-5), 113.91 (C(CH₃)₃), 91.88 (C-1'), 89.68 (C-4'), 84.26 (C-2'), 81.93 (C-3'), 64.19 (C-5'), 27.24 (CH₃), 25.92 (C(CH₃)₃), 25.31 (CH₃), 18.79 (C-6-CH₂CH₃), 12.44 (C-6-CH₂CH₃), -5.23 (Si(CH₃)₂).

5-Fluoro-6-methyluridine (7). A stirred solution of 5'-*O*-(*t*-butyldimethylsilyl)-2',3'-*O*-isopropylidene-5-fluoro-6-methyluridine **22** (1.43 g, 3.32 mmol) in water (10 mL) was treated with 50% aqueous (10 mL) at 0°C, brought to room temperature, and stirred for an additional 2 h. The reaction mixture was concentrated under vacuum and was purified by column chromatography with a gradient of MeOH in DCM (6% to 10%) to give a product as a yellowish solid (0.84 g, 92%). ¹H NMR (500 MHz, MeOD): δ 5.53 (1H, d, *J* = 4.0 Hz, *H*-1'), 4.78 (1H, dd, *J* = 6.5, 4.0 Hz, *H*-2'), 4.33 (1H, t, *J* = 6.5 Hz, *H*-3'), 3.93 – 3.90 (1H, m, *H*-4'), 3.82 (1H, dd, *J* = 12.0, 3.0 Hz, 1 x *H*-5'), 3.69 (1H, dd, *J* = 12.0, 5.5 Hz, 1 x *H*-5'), 2.38 (3H, d, *J*_{H-F} = 4.0 Hz, C-6-CH₃); ¹³C NMR (125 MHz, MeOD): δ_C 158.75 (d, ²*J*_{C-F} = 27.8 Hz, C-4), 150.77 (C-2), 140.20 (d, ²*J*_{C-F} = 24.5 Hz, C-6), 139.71 (d, ¹*J*_{C-F} = 225.5 Hz, C-5), 94.12 (C-1'), 86.32 (C-4'), 72.81 (C-2'), 71.40 (C-3'), 63.62 (C-5'), 12.02 (d, ³*J*_{C-F} = 3.80 Hz, C-6-CH₃); MS (ES+) *m/z*: 299.2 (M + Na⁺, 100%), Accurate mass: C₁₀H₁₃FN₂O₆ required 276.22 found 299 (M + Na⁺). Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, *t*_R = 5.01 min.

5-Fluoro-6-ethyluridine (8). A stirred solution of 5'-*O*-(*t*-butyldimethylsilyl)-2',3'-*O*-isopropylidene-5-fluoro-6-ethyluridine **23** (0.75 g, 1.68 mmol) in water (10 mL) was treated with 50% aqueous (10 mL) at 0°C, brought to room temperature, and stirred for an additional 2 h. The reaction mixture was concentrated under vacuum and was purified by column chromatography with a gradient of MeOH in DCM (6% to 10%) to give a product as a yellowish solid (0.38 g, 80%). ¹H NMR (500 MHz, MeOD): δ 5.34 (1H, d, *J* = 4.0 Hz, *H*-1'), 4.64 (1H, dd, *J* = 6.5, 4.0 Hz, *H*-2'), 4.19 (1H, t, *J* = 6.5 Hz, *H*-3'), 3.79 – 3.76 (1H, m, *H*-4'), 3.67 (1H, dd, *J* = 12.0, 3.0 Hz, 1 x *H*-5'), 3.59 (1H, dd, *J* = 12.0, 5.5 Hz, 1 x *H*-5'), 2.73 – 2.60 (2H, m, C-6-CH₂CH₃), 1.18 (3H, t, *J* = 7.5 Hz, C-6-CH₂CH₃); ¹³C NMR (125 MHz, MeOD): δ_C 157.50 (d, ²*J*_{C-F} = 28.8 Hz, C-4), 149.52 (C-2), 143.68 (d, ²*J*_{C-F} = 23.8 Hz, C-6), 137.62 (d, ¹*J*_{C-F} = 225.0 Hz, C-

5), 92.71 (C-1'), 85.01 (C-4'), 71.38 (C-2'), 70.06 (C-3'), 62.38 (C-5'), 18.25 (d, $^3J_{C-F}$ = 2.5 Hz, C-6-CH₂CH₃), 11.31 (C-6-CH₂CH₃); MS (ES+) m/z : 313.25 (M + Na⁺, 100%), Accurate mass: C₁₁H₁₅FN₂O₆ required 290 found 313 (M + Na⁺). Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, t_R = 6.05 min.

General Method for the Preparation of phosphorochloridates (24).⁴⁵ Anhydrous triethylamine (2.0 mol eq.) was added dropwise at -78 °C to a stirred solution of the appropriate aryl dichlorophosphate (1.0 mol eq.) and an appropriate amino acid ester (1.0 mol eq.) in anhydrous DCM under argon atmosphere. Following the addition, the reaction mixture was allowed to slowly warm to room temperature and stirred for 1-2 hours. A formation of a desired compound was monitored by ³¹P NMR. After the reaction was completed, the solvent was evaporated under reduced pressure and the resulting residue was re-dissolved in anhydrous Et₂O and filtered. The filtrate was reduced to dryness to give a crude product as an oil, which was in some cases used without further purification in the next step. Most of aryl phosphorochloridates, in particular those obtained from the amino acid tosylate salt were purified by flash column chromatography using EtOAc/Hexane (7:3) as an eluent.

General method for the preparation of phosphoramidates.

To a stirring solution of nucleoside analogue (1.0 mol/eq.) in anhydrous THF, an appropriate phosphorochloridate (3.0 mol/eq.) dissolved in anhydrous THF was added dropwise under an argon atmosphere. To that reaction mixture NMI (5.0 mol/eq.) was added dropwise over 5 minutes at -78° C under an argon atmosphere. After 15 minutes, the reaction mixture was let to rise to room temperature and stirred overnight (16 - 18h). The solvent was removed under reduced pressure and the residue was re-dissolved in DCM and washed with 0.5 M HCl (3 x 3 mL). The organic layer was dried over MgSO₄, filtered, reduced to dryness and purified by column chromatography with gradient of eluent (DCM/MeOH 99:1 to 97:3 to 95:5) followed by preparative TLC purification (DCM/MeOH 95:5).

5-Fluoro-6-iodouridine-5'-O-[phenyl-(pentoxyl-L-alaninyl)] phosphate (25).

Prepared according to the standard procedure from 5-fluoro-6-iodouridine **5** (0.20 g, 0.51 mmol), NMI (0.20 mL, 2.57 mmol), phenyl-(pentoxyl-L-alaninyl)-

phosphorochloridate (0.43 g, 1.03 mmol). After column purification on silica gel **25** was obtained as a yellowish solid (0.021 g, 6%). ^{31}P NMR (202 MHz, MeOD): δ_{P} 3.52, 3.46; ^1H NMR (500 MHz, MeOD): δ_{H} 7.36 – 7.33 (2H, m, *H*-Ar), 7.24 – 7.22 (2H, m, *H*-Ar), 7.19 – 7.16 (1H, m, *H*-Ar), 5.96 (1H, apparent t, $J = 3.0$ Hz, *H*-1'), 4.73, 4.70 (1H, 2 x dd, $J = 6.0, 2.5$ Hz, *H*-2'), 4.53 – 4.34 (2H, m, *H*-3', 1 x *H*-5'), 4.27 – 4.22 (1H, m, 1 x *H*-5'), 4.18 – 4.02 (2H, m, OCH_2), 3.98 – 3.94 (1H, m, *H*-4'), 3.64 – 3.59 (1H, m, NHCHCH_3), 1.71 – 1.60 (6H, m, 3 x CH_2 ester), 1.39 – 1.32 (3H, m, NHCHCH_3), 0.96 – 0.91 (3H, m, CH_3); ^{13}C NMR (125 MHz, MeOD): δ_{C} 173.59, 172.90 ($\text{C}=\text{O}$ ester), 156.56 (*C*-4), 151.75, 151.26 (*C*-2), 149.19 (*C*-Ar), 145.28 (d, $^1J_{\text{C-F}} = 205.0$ Hz, *C*-5), 129.28, 127.57, 124.61, 120.12 (*CH*-Ar), 108.98 (*C*-6), 102.19 (*C*-1'), 83.02, 82.51 (*C*-4'), 72.29 (*C*-2'), 70.59, 69.89 (*C*-3'), 65.08 (*C*-5'), 64.24 (OCH_2), 50.06 (NHCHCH_3), 28.00, 21.96, 21.06 (CH_2), 19.37 (NHCHCH_3), 12.90 ($\text{O}(\text{CH}_2)_4\text{CH}_3$); MS (ES+) m/z : 708.0 ($\text{M} + \text{Na}^+$, 100%), Accurate mass: $\text{C}_{23}\text{H}_{30}\text{FIN}_3\text{O}_{10}\text{P}$ required 685.38 found 708.0 ($\text{M} + \text{Na}^+$); Reverse-phase HPLC, eluting with $\text{H}_2\text{O}/\text{AcCN}$ from 100/0 to 0/100 in 35 min, $F = 1$ mL/min, $\lambda = 254$, two peaks for two diastereoisomers with $t_{\text{R}} = 17.11, 17.43$ min.

5-Fluoro-6-iodouridine-5'-*O*-[phenyl-(cyclohexoxy-L-alaninyl)] phosphate (**26**).

Prepared according to the standard procedure from 5-fluoro-6-iodouridine **5** (0.23 g, 0.59 mmol), NMI (0.23 mL, 2.96 mmol), phenyl-(cyclohexoxy-L-alaninyl)-phosphorochloridate (0.40 g, 1.18 mmol). After column purification on silica gel **26** was obtained as a yellowish solid (0.028 g, 7%). ^{31}P NMR (202 MHz, MeOD): δ 3.68, 3.54; ^1H NMR (500 MHz, MeOD): δ 7.37 – 7.33 (2H, m, *H*-Ar), 7.24 – 7.23 (2H, m, *H*-Ar), 7.20 – 7.17 (1H, m, *H*-Ar), 5.97 – 5.95 (1H, m, *H*-1'), 4.51 – 4.34 (2H, m, *H*-2', OCH ester), 4.51 – 4.34 (2H, m, *H*-3', 1 x *H*-5'), 4.28 – 4.23 (1H, m, 1 x *H*-5'), 4.05 – 4.01 (1H, m, *H*-4'), 3.96 – 3.89 (1H, m, NHCHCH_3), 1.83 – 1.73 (5H, m, CH_2 ester), 1.58 – 1.54 (1H, m, CH_2 ester), 1.49 – 1.38 (4H, m, CH_2 ester), 1.37, 1.32 (3H, 2 x dd, $J = 7.0, 1.0$ Hz, NHCHCH_3); ^{13}C NMR (125 MHz, MeOD): δ_{C} 174.52, 174.4 (2 x d, $^3J_{\text{C-P}} = 5.4$ Hz, $\text{C}=\text{O}$ ester), 156.40 (d, $^2J_{\text{C-F}} = 32.0$ Hz, *C*-4), 152.30, 152.25 (2 x d, $^4J_{\text{C-F}} = 4.70$ Hz, *C*-2), 148.67, 148.52 (*C*-Ar), 145.36, 145.30 (2 x d, $^1J_{\text{C-F}} = 228.0$ Hz, *C*-5), 130.69, 129.34, 126.03 (*CH*-Ar), 121.68 (d, $^3J_{\text{C-P}} = 4.6$ Hz, *CH*-Ar), 104.94, 104.78 (2 x d, $^2J_{\text{C-F}} = 39.0$ Hz, *C*-6), 103.58, 103.43 (*C*-1'), 84.01, 83.55 (d, $^3J_{\text{C-P}} = 7.10$ Hz, *C*-4'), 75.01, 74.99 (OCH), 73.70, 73.55 (*C*-2'), 71.28,

70.69 (*C*-3'), 68.52, 67.48 (2 x d, $^2J_{C-P}$ = 5.5 Hz, *C*-5'), 51.63 (d, $^2J_{C-P}$ = 5.5 Hz, NHCHCH₃), 32.49, 32.47, 32.39, 26.45, 26.43, 26.41, 24.69, 24.62 (CH₂), 20.85, 20.76 (2 x d, $^3J_{C-P}$ = 5.75 Hz, NHCHCH₃); MS (ES⁺) *m/z*: 720.1 (*M* + Na⁺, 100%), Accurate mass: C₂₄H₃₀FIN₃O₁₀P required 697.39 found 720.1 (*M* + Na⁺); Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, *F* = 1 mL/min, λ = 254, two peaks for two diastereoisomers with *t_R* = 17.60, 17.64 min.

5-Fluoro-6-iodouridine-5'-*O*-[1-naphthyl-(benzoxy-L-alaninyl)] phosphate (27).

Prepared according to the general procedure from 5-fluoro-6-iodouridine **5** (0.18 g, 0.46 mmol), NMI (0.18 mL, 2.32 mmol), 1-naphthyl-(benzoxy-L-alaninyl)-phosphorochloridate (0.37 g, 0.93 mmol). After column purification on silica gel **27** was obtained as a yellowish solid (0.017 g, 5%). ³¹P NMR (202 MHz, MeOD): δ 3.89, 3.74; ¹H NMR (500 MHz, MeOD): δ 8.19 – 8.16 (1H, m, *H*-Ar), 7.89 – 7.85 (1H, m, *H*-Ar), 7.69 – 7.65 (1H, m, *H*-Ar), 7.54 – 7.47 (3H, m, *H*-Ar), 7.41 – 7.36 (1H, m, *H*-Ar), 7.33 – 7.25 (5H, m, *H*-Ar), 5.96 – 5.94 (1H, m, *H*-1'), 5.01 – 4.96 (2H, m, CH₂Ph), 4.73, 4.68 (1H, 2 x dd, *J* = 6.5, 3.0 Hz, *H*-2'), 4.54 – 4.41 (2H, m, *H*-3', 1 x *H*-5'), 4.33 – 4.27 (1H, m, 1 x *H*-5'), 4.12 – 4.02 (2H, m, *H*-4', NHCHCH₃), 1.35, 1.30 (3H, 2 x dd, *J* = 7.0, 0.5 Hz, NHCHCH₃); ¹³C NMR (125 MHz, MeOD): δ_C 174.40, 174.26 (*C*=O, ester), 156.50 (*C*-4), 152.40, 152.20 (*C*-2), 148.67 (*C*-Ar), 137.20 (d, $^3J_{C-P}$ = 4.5 Hz, *C*-Ar), 136.10 (*C*-Ar), 135.30, 135.22 (2 x d, $^1J_{C-F}$ = 225.0 Hz, *C*-5), 129.68, 129.58, 129.36, 129.25, 129.26, 128.76, 128.69, 127.75, 127.71, 127.48, 127.46, 126.57, 126.54, 125.90, 122.90, 122.75 (CH-Ar), 116.30, 116.21 (2 x d, $^3J_{C-P}$ = 3.4 Hz CH-Ar), 108.74 (*C*-6), 103.63, 103.44 (*C*-1'), 84.00, 83.64 (2 x d, $^3J_{C-P}$ = 7.25 Hz, *C*-4'), 74.05, 73.88 (*C*-2'), 71.28, 70.72 (*C*-3'), 68.52 (d, $^2J_{C-P}$ = 5.8 Hz, *C*-5'), 67.97, 67.85 (OCH₂Ph), 67.71 (d, $^2J_{C-P}$ = 5.4 Hz, *C*-5'), 51.70 (NHCHCH₃), 20.86, 20.74 (2 x d, $^3J_{C-P}$ = 6.4 Hz, NHCHCH₃); MS (ES⁺) *m/z*: 755.42 (*M* + Na⁺, 100%), Accurate mass: C₂₉H₂₈FIN₃O₁₀P required 755.42 found 778.0 (*M* + Na⁺); Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, *F* = 1 mL/min, λ = 254, two peaks for two diastereoisomers with *t_R* = 17.21, 17.37 min.

5-Fluoro-6-azidouridine-5'-*O*-[phenyl-(ethoxy-L-alaninyl)] phosphate (28).

Prepared according to the general procedure from 5-fluoro-6-azidouridine **6** (0.15 g, 0.49 mmol), NMI (0.19 mL, 2.47 mmol), phenyl-(ethoxy-L-alaninyl)-phosphorochloridate (0.28 g, 0.99 mmol). After column purification on silica gel **28** was obtained as a yellowish solid (0.014 g, 5%). ³¹P NMR (202 MHz, MeOD): δ_P

3.69, 3.53; ^1H NMR (500 MHz, MeOD): δ_{H} 7.38 – 7.35 (2H, m, *H*-Ar), 7.25 – 7.18 (3H, m, *H*-Ar), 5.95, 5.92 (1H, 2 \times d, J = 2.80 Hz, *H*-1'), 4.67 – 4.62 (1H, m, *H*-2'), 4.47 – 4.34 (2H, m, *H*-3', 1 \times *H*-5'), 4.28 – 4.22 (1H, m, 1 \times *H*-5'), 4.18 – 4.10 (2H, m, OCH_2CH_3), 4.00–3.92 (2H, m, NHCHCH_3 , *H*-4'), 1.36, 1.32 (3H, 2 \times d, J = 7.17 Hz, NHCHCH_3), 1.27 – 1.23 (m, 3H, OCH_2CH_3); ^{13}C NMR (125 MHz, MeOD): δ_{C} 175.11, 174.97 (2 \times d, $^3J_{\text{C-P}}$ = 5.60 Hz, C=O, ester), 157.85 (d, $^2J_{\text{C-F}}$ = 24.1 Hz, C-4), 152.25 (apparent t, $^2J_{\text{C-P}}$ = 12.75 Hz, O-C-Ar), 149.32, 149.22 (C-2), 139.36 (d, $^2J_{\text{C-F}}$ = 21.3 Hz, C-6), 136.26, 134.45 (2 \times d, $^1J_{\text{C-F}}$ = 235 Hz, C-5), 130.0, 121.47, 121.43, 121.56, 121.53, 121.47, 121.43 (CH-Ar), 92.96, 92.84 (C-1'), 83.60, 83.33 (2 \times d, $^3J_{\text{C-P}}$ = 7.12 Hz, C-4'), 73.41, 73.30 (C-2'), 70.97, 70.50 (C-3'), 68.22, 67.38 (2 \times d, $^2J_{\text{C-P}}$ = 6.10 Hz, C-5'), 62.41, 61.37 (OCH_2CH_3), 51.50 (d, $^2J_{\text{C-P}}$ = 5.17 Hz, NHCHCH_3), 20.15, 20.53 (2 \times d, $^3J_{\text{C-P}}$ = 6.39 Hz, NHCHCH_3), 14.97 (OCH_2CH_3); MS (ES+) m/z : 581.1 ($\text{M} + \text{Na}^+$, 100%), Accurate mass: $\text{C}_{20}\text{H}_{24}\text{FN}_6\text{O}_{10}\text{P}$ required 558.1 found 581.1 ($\text{M} + \text{Na}^+$); Reverse-phase HPLC, eluting with $\text{H}_2\text{O}/\text{AcCN}$ from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, two peaks for two diastereoisomers with t_{R} = 14.68, 14.95 min.

5-Fluoro-6-azidouridine-5'-*O*-[phenyl-(hexoxy-L-alaninyl)] phosphate (29).

Prepared according to the general procedure from 5-fluoro-6-azidouridine **6** (0.10 g, 0.33 mmol), NMI (0.13 mL, 1.65 mmol), phenyl-(hexoxy-L-alaninyl)-phosphorochloridate (0.23 g, 0.66 mmol). After column purification on silica gel **29** was obtained as a yellowish solid (0.008 g, 4%). ^{31}P NMR (202 MHz, MeOD): δ_{P} 3.67, 3.51; ^1H NMR (500 MHz, MeOD): δ_{H} 7.38 – 7.35 (2H, m, *H*-Ar), 7.25 – 7.18 (3H, m, *H*-Ar), 5.95, 5.93 (1H, 2 \times d, J = 2.75 Hz, *H*-1'), 4.67 – 4.62 (1H, m, *H*-2'), 4.47 – 4.34 (2H, m, *H*-3', 1 \times *H*-5'), 4.28 – 4.22 (1H, m, 1 \times *H*-5'), 4.14 – 4.05 (2H, m, OCH_2), 4.00 – 3.93 (2H, m, NHCHCH_3 , *H*-4'), 1.66 – 1.60 (2H, m, $\text{OCH}_2\text{CH}_2(\text{CH}_2)_3\text{CH}_3$), 1.40 – 1.31 (9H, m, 3 \times CH_2 , NHCHCH_3), 0.93 – 0.90 (3H, m, CH_3); ^{13}C NMR (125 MHz, MeOD): δ_{C} 175.17, 175.03 (2 \times d, $^3J_{\text{C-P}}$ = 5.90 Hz, C=O, ester), 157.80 (d, $^2J_{\text{C-F}}$ = 23.7 Hz, C-4), 152.25 (apparent t, $^2J_{\text{C-P}}$ = 12.9 Hz, O-C-Ar), 149.42, 149.37 (C-2), 139.35 (d, $^2J_{\text{C-F}}$ = 20.92 Hz, C-6), 136.27, 134.47 (2 \times d, $^1J_{\text{C-F}}$ = 232.9 Hz, C-5), 130.70, 126.08, 126.04, 121.58, 121.54, 121.47, 121.43 (CH-Ar), 92.97, 92.84 (C-1'), 83.65, 83.33 (2 \times d, $^3J_{\text{C-P}}$ = 7.11 Hz, C-4'), 73.42, 73.29 (C-2'), 70.96, 70.50 (C-3'), 68.24, 67.39 (2 \times d, $^2J_{\text{C-P}}$ = 5.44 Hz, C-5'), 66.49, 66.45 (OCH_2), 49.87 (NHCHCH_3), 32.88, 32.57, (OCH_2CH_2), 29.66, 26.63, 26.60, 23.59, 23.58

(CH₂), 20.70, 20.59 (2 × d, ³J_{C-P} = 6.9 Hz, NHCHCH₃), 14.34 (O(CH₂)₅CH₃); MS (ES⁺) *m/z*: 581.1 (M + Na⁺, 100%), Accurate mass: C₂₄H₃₂FN₆O₁₀P required 614.52 found 637.2 (M + Na⁺); Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, two peaks for two diastereoisomers with *t*_R = 18.99, 19.23 min.

5-Fluoro-6-azidouridine-5'-O-[phenyl-(benzoxy-L-alaninyl)] phosphate (30).

Prepared according to the general procedure from 5-fluoro-6-azidouridine **6** (0.18 g, 0.59 mmol), NMI (0.24 mL, 2.90 mmol), phenyl-(benzoxy-L-alaninyl)-phosphorochloridate (0.42 g, 1.18 mmol). After column purification on silica gel **30** was obtained as a yellowish solid (0.026 g, 7%). ³¹P NMR (202 MHz, MeOD): δ_P 3.71, 3.45; ¹H NMR (500 MHz, MeOD): δ_H 7.37 – 7.32 (7H, m, *H*-Ar), 7.22 – 7.16 (3H, m, *H*-Ar), 5.96 (1H, 2 × d, *J* = 3.0 Hz, *H*-1'), 5.17 – 5.11 (2H, m, CH₂Ph), 4.65, 4.62 (1H, 2 × dd, *J* = 6.5, 3.0 Hz, *H*-2'), 4.45 – 4.33 (2H, m, *H*-3', 1 × *H*-5'), 4.26 – 4.21 (1H, m, 1 × *H*-5'), 4.04 – 3.95 (2H, m, NHCHCH₃, *H*-4'), 1.37, 1.33 (3H, dd, *J* = 7.0, 1.0 Hz, NHCHCH₃); ¹³C NMR (125 MHz, MeOD): δ_C 173.39, 173.26 (2 × d, ³J_{C-P} = 4.75 Hz, C=O, ester), 157.76 (d, ²J_{C-F} = 24.8 Hz, C-4), 149.26, 149.15 (C-2), 152.36 (C-Ar), 139.31 (C-6), 136.18 (C-Ar), 135.30, 135.21 (2 × d, ¹J_{C-F} = 224.0 Hz, C-5), 130.10, 130.04, 129.58, 129.52, 128.86, 128.79, 127.65, 127.55 (CH-Ar), 120.06, 120.0 (CH-Ar), 92.90, 92.81 (C-1'), 83.45, 83.25 (C-4'), 73.45, 73.28 (C-2'), 70.94, 70.50 (C-3'), 68.50 (d, ²J_{C-P} = 5.4 Hz, C-5'), 68.00, 67.80 (OCH₂Ph), 67.70 (d, ²J_{C-P} = 5.4 Hz, C-5'), 51.70 (NHCHCH₃), 20.70, 20.55 (2 × d, ³J_{C-P} = 6.4 Hz, NHCHCH₃); MS (ES⁺) *m/z*: 643.0 (M + Na⁺, 100%), Accurate mass: C₂₅H₂₆FN₆O₁₀P required 620.48 found 643.0 (M + Na⁺); Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, two peaks for two diastereoisomers with *t*_R = 17.60, 17.76 min.

5-Fluoro-6-azidouridine-5'-O-[1-naphthyl-(hexoxy-L-alaninyl)] phosphate (31).

Prepared according to the general procedure from 5-fluoro-6-azidouridine **6** (0.18 g, 0.59 mmol), NMI (0.23 mL, 2.97 mmol), 1-naphthyl-(hexoxy-L-alaninyl)-phosphorochloridate (0.47 g, 1.19 mmol). After column purification on silica gel **31** was obtained as a yellowish solid (0.019 g, 5%). ³¹P NMR (202 MHz, MeOD): δ_P 3.89; ¹H NMR (500 MHz, MeOD): δ_H 8.08 – 8.06 (1H, m, *H*-Ar), 7.78 – 7.74 (1H, m, *H*-Ar), 7.59 – 7.57 (1H, m, *H*-Ar), 7.45 – 7.30 (3H, m, *H*-Ar), 7.32 – 7.28 (1H, m, *H*-Ar), 5.81, 5.79 (1H, 2 × d, *J* = 3.0 Hz, *H*-1'), 4.53, 4.50 (1H, 2 × dd, *J* = 6.5, 3.0 Hz,

H-2'), 4.38 – 4.26 (2H, m, *H*-3', 1 x *H*-5'), 4.23 – 4.17 (1H, m, 1 x *H*-5'), 3.93 – 3.85 (4H, m, OCH₂, NHCHCH₃, *H*-4'), 1.45 – 1.38 (2H, m, OCH₂CH₂(CH₂)₃CH₃), 1.24, 1.20 (3H, 2 x dd, *J* = 7.0, 0.5 Hz, NHCHCH₃), 1.17 – 1.10 (6H, m, 3 x CH₂), 0.78 – 0.73 (3H, m, CH₃); ¹³C NMR (125 MHz, MeOD): δ_C 175.18, 175.0 (2 × d, ³*J*_{C-P} = 4.50 Hz, C=O, ester), 157.75 (d, ²*J*_{C-F} = 24.0 Hz, C-4), 149.25, 149.17 (C-2), 148.10 (d, ²*J*_{C-P} = 7.0 Hz, O-C-Ar), 139.30 (d, ²*J*_{C-F} = 19.5 Hz, C-6), 136.29 (d, ³*J*_{C-P} = 2.0 Hz, C-Ar), 135.32, 135.29 (2 × d, ¹*J*_{C-F} = 225.0 Hz, C-5), 128.87, 128.79, 127.75, 127.73, 127.42, 127.38 (CH-Ar), 126.54, 126.52 (2 × d, ³*J*_{C-P} = 1.5 Hz, CH-Ar), 125.83, 122.95, 122.78, 116.23, 116.20, 116.19, 116.17 (CH-Ar), 92.98, 92.85 (C-1'), 83.68, 83.36 (2 × d, ³*J*_{C-P} = 7.0 Hz, C-4'), 73.46, 73.31 (C-2'), 70.95, 70.52 (C-3'), 68.51, 67.66 (2 × d, ²*J*_{C-P} = 5.5 Hz, C-5'), 66.52, 66.45 (OCH₂), 51.64 (NHCHCH₃), 32.57, 32.54 (OCH₂CH₂), 29.60, 26.60, 26.57, 23.57, 23.55 (CH₂), 20.78, 20.64 (2 × d, ³*J*_{C-P} = 6.5 Hz, NHCHCH₃), 14.35, 14.33 (O(CH₂)₅CH₃); MS (ES+) *m/z*: 687.58 (M + Na⁺, 10%), Accurate mass: C₂₈H₃₄FN₆O₁₀P required 664.58 found 687.2 (M + Na⁺), 1351.4 (2 x M + Na⁺), Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, two peaks for two diastereoisomers with *t*_R = 23.08, 23.51 min.

5-Fluoro-6-azidouridine-5'-O-[1-naphthyl-(benzoxy-L-alaninyl)] phosphate (32).

Prepared according to the general procedure from 5-fluoro-6-azidouridine **6** (0.17 g, 0.56 mmol), NMI (0.23 mL, 2.80 mmol), 1-naphthyl-(benzoxy-L-alaninyl)-phosphorochloridate (0.45 g, 1.12 mmol). After column purification on silica gel **32** was obtained as a yellowish solid (0.029 g, 8%). ³¹P NMR (202 MHz, MeOD): δ_P 3.95, 3.79; ¹H NMR (500 MHz, MeOD): δ_H 8.19 – 8.17 (1H, m, *H*-Ar), 7.89 – 7.86 (1H, m, *H*-Ar), 7.70 (1H, apparent d, *J* = 12.5 Hz, *H*-Ar), 7.55 – 7.48 (3H, m, *H*-Ar), 7.43 – 7.38 (1H, m, *H*-Ar), 7.32 – 7.29 (5H, m, *H*-Ar), 5.91, 5.90 (1H, 2 x d, *J* = 3.0 Hz, *H*-1'), 5.09 – 5.02 (2H, m, CH₂Ph), 4.65, 4.60 (1H, 2 x dd, *J* = 6.0, 3.0 Hz, *H*-2'), 4.48 – 4.37 (2H, m, *H*-3', 1 x *H*-5'), 4.33 – 4.28 (1H, m, 1 x *H*-5'), 4.13 – 4.05 (1H, m, NHCHCH₃), 4.02 – 3.98 (1H, m, *H*-4'), 1.35, 1.32 (3H, 2 x dd, *J* = 7.0, 1.0 Hz, NHCHCH₃); ¹³C NMR (125 MHz, MeOD): δ_C 173.39, 173.26 (2 × d, ³*J*_{C-P} = 4.75 Hz, C=O, ester), 157.76 (d, ²*J*_{C-F} = 24.8 Hz, C-4), 149.26, 149.15 (C-2), 148.07 (d, ²*J*_{C-P} = 7.3 Hz, O-C-Ar), 139.31, 139.26 (2 x d, ²*J*_{C-F} = 19.1 Hz, C-6), 137.18 (d, ³*J*_{C-P} = 4.5 Hz, C-Ar), 136.28 (C-Ar), 135.28, 135.25 (2 × d, ¹*J*_{C-F} = 224.8 Hz, C-5), 129.58, 129.54, 129.31, 129.23, 129.18, 128.86, 128.79, 127.75, 127.73, 127.46, 127.41,

126.53, 126.51, 125.87, 122.95, 122.75 (CH-Ar), 116.31, 116.21 (2 x d, $^3J_{C-P}$ = 3.4 Hz CH-Ar), 92.97, 92.81 (C-1'), 83.65, 83.35 (2 x d, $^3J_{C-P}$ = 6.8 Hz, C-4'), 73.45, 73.28 (C-2'), 70.94, 70.50 (C-3'), 68.52 (d, $^2J_{C-P}$ = 5.4 Hz, C-5'), 68.01, 67.80 (CH₂Ph), 67.71 (d, $^2J_{C-P}$ = 5.4 Hz, C-5'), 51.70 (NHCHCH₃), 20.58, 20.45 (2 x d, $^3J_{C-P}$ = 6.4 Hz, NHCHCH₃); MS (ES+) m/z : 693.2 (M + Na⁺, 30%), Accurate mass: C₂₉H₂₈FN₆O₁₀P required 670.54 found 693.2 (M + Na⁺), 1363.4 (2 x M + Na⁺), Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, two peaks for two diastereoisomers with t_R = 17.20, 17.53 min.

5-Fluoro-6-methyluridine-5'-O-[1-phenyl-(hexoxy-L-alaninyl)] phosphate (33).

Prepared according to the general procedure from 5-fluoro-6-methyluridine **7** (0.18 g, 0.65 mmol), NMI (0.26 mL, 3.26 mmol), phenyl-(hexoxy-L-alaninyl)-phosphorochloridate (0.45 g, 1.30 mmol). After column purification on silica gel **33** was obtained as an off-white solid (0.034 g, 9%). ^{31}P NMR (202 MHz, MeOD): δ_P 3.56, 3.44; ^1H NMR (500 MHz, MeOD): δ_H 7.37 – 7.33 (2H, m, *H*-Ar), 7.25 – 7.22 (2H, m, *H*-Ar), 7.22 – 7.17 (1H, m, *H*-Ar), 5.52, 5.50 (1H, 2 x d, J = 2.75 Hz, *H*-1'), 4.77, 4.74 (1H, 2 x d, J = 6.0, 3.0 Hz, *H*-2'), 4.49 – 4.34 (2H, m, *H*-3', 1 x *H*-5'), 4.27 – 4.21 (1H, m, 1 x *H*-5'), 4.14 – 3.93 (4H, m, OCH₂, NHCHCH₃, *H*-4'), 2.37, 2.36 (3H, 2 x d, J_{C-F} = 4.0 Hz, CH₃), 1.65 – 1.58 (2H, m, OCH₂CH₂(CH₂)₃CH₃), 1.38 – 1.31 (9H, m, 3 x CH₂, NHCHCH₃), 0.93 – 0.89 (3H, m, CH₃); ^{13}C NMR (125 MHz, MeOD): δ_C 175.13, 174.99 (2 x d, $^3J_{C-P}$ = 6.0 Hz, C=O, ester), 158.85 (d, $^2J_{C-F}$ = 26.6 Hz, C-4), 152.30, 152.26 (2 x d, $^2J_{C-P}$ = 5.5 Hz, O-C-Ar), 150.57, 150.45 (C-2), 139.95 (d, $^2J_{C-F}$ = 24.4 Hz, C-6), 139.72, 139.67 (2 x d, $^1J_{C-F}$ = 225.5 Hz, C-5), 130.07, 126.08, 126.03, 121.66, 121.62, 121.50, 121.47 (CH-Ar), 94.63, 94.51 (C-1'), 83.70, 83.38 (2 x d, $^3J_{C-P}$ = 7.40 Hz, C-4'), 73.17, 73.04 (C-2'), 71.26, 70.75 (C-3'), 68.34, 67.46 (2 x d, $^2J_{C-P}$ = 5.50 Hz, C-5'), 66.49, 66.42 (OCH₂), 51.54 (NHCHCH₃), 32.88, 32.57 (OCH₂CH₂), 29.67, 26.65, 26.62, 23.59, 23.58 (CH₂), 20.73, 20.64 (2 x d, $^3J_{C-P}$ = 6.0 Hz, NHCHCH₃), 14.35 (O(CH₂)₅CH₃), 11.96 (d, $^3J_{C-F}$ = 3.6 Hz, C-6-CH₃); MS (ES+) m/z : 610.2 (M + Na⁺, 100%), Accurate mass: C₂₅H₃₅FN₃O₁₀P required 587.53 found 610.2 (M + Na⁺), 1197.4 (2 x M + Na⁺); Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, two peaks for two diastereoisomers with t_R = 17.73, 17.91 min.

5-Fluoro-6-methyluridine-5'-O-[phenyl-(benzoxy-L-alaninyl)] phosphate (34).

Prepared according to the general procedure from 5-fluoro-6-methyluridine **7** (0.15 g,

0.54 mmol), NMI (0.22 mL, 2.72 mmol), phenyl-(benzoxy-L-alaninyl)-phosphorochloridate (0.38 g, 1.08 mmol). After column purification on silica gel **34** was obtained as an off-white solid (0.026 g, 8%). ^{31}P NMR (202 MHz, MeOD): δ_{P} 3.57, 3.39; ^1H NMR (500 MHz, MeOD): δ_{H} 7.38 – 7.30 (7H, m, *H*-Ar), 7.22 – 7.16 (3H, m, *H*-Ar), 5.51, 5.49 (1H, 2 x d, $J = 3.0$ Hz, *H*-1'), 5.17 – 5.09 (2H, m, CH_2Ph), 4.76, 4.72 (1H, 2 x dd, $J = 6.5, 3.0$ Hz, *H*-2'), 4.48 – 4.33 (2H, m, *H*-3', 1 x *H*-5'), 4.25 – 4.18 (1H, m, 1 x *H*-5'), 4.04 – 3.95 (2H, m, NHCHCH_3 , *H*-4'), 2.35, 2.33 (3H, 2 x d, $J = 4.0$ Hz, CH_3), 1.37, 1.31 (3H, 2 x dd, $J = 7.0, 1.0$ Hz, NHCHCH_3); ^{13}C NMR (125 MHz, MeOD): δ_{C} 173.37, 173.30 (2 x d, $^3J_{\text{C-P}} = 5.10$ Hz, C=O , ester), 157.46, 157.40 (2 x d, $^2J_{\text{C-F}} = 26.2$ Hz, *C*-4), 150.81, 150.76 (*C*-2), 147.96 (*C*-Ar), 139.16, 139.09 (d, $^2J_{\text{C-P}} = 7.5$ Hz, *O*-*C*-Ar), 138.53, 138.50 (2 x d, $^2J_{\text{C-F}} = 24.6$ Hz, *C*-6), 136.58 (d, $^1J_{\text{C-F}} = 185.5$ Hz, *C*-5), 129.33, 129.27, 128.17, 128.15, 127.91, 127.85, 124.64, 124.62 (*CH*-Ar), 120.23, 120.06 (2 x d, $^2J_{\text{C-P}} = 4.5$ Hz *CH*-Ar), 93.22, 93.06 (*C*-1'), 82.26, 81.92 (2 x d, $^3J_{\text{C-P}} = 7.2$ Hz, *C*-4'), 71.74, 71.60 (*C*-2'), 69.80, 69.27 (*C*-3'), 66.95 (d, $^2J_{\text{C-P}} = 5.8$ Hz, *C*-5'), 66.58, 66.46 (OCH_2Ph), 66.04 (d, $^2J_{\text{C-P}} = 5.8$ Hz, *C*-5'), 50.16 (NHCHCH_3), 19.13, 19.05 (2 x d, $^3J_{\text{C-P}} = 6.4$ Hz, NHCHCH_3), 10.54 (d, $^3J_{\text{C-F}} = 3.3$ Hz, *C*-6- CH_3); MS (ES+) m/z : 616.1 ($\text{M} + \text{Na}^+$), Accurate mass: $\text{C}_{26}\text{H}_{29}\text{FN}_3\text{O}_{10}\text{P}$ required 593.49 found 616.1 ($\text{M} + \text{Na}^+$), 1209.3 (2 x $\text{M} + \text{Na}^+$), Reverse-phase HPLC, eluting with $\text{H}_2\text{O}/\text{AcCN}$ from 100/0 to 0/100 in 35 min, $F = 1$ mL/min, $\lambda = 254$, two peaks for two diastereoisomers with $t_{\text{R}} = 15.15, 15.35$ min.

5-Fluoro-6-methyluridine-5'-O-[1-naphthyl-(neopentoxo-L-alaninyl)] phosphate (35). Prepared according to the general procedure from 5-fluoro-6-methyluridine **7** (0.10 g, 0.36 mmol), NMI (0.14 mL, 1.81 mmol), 1-naphthyl-(neopentoxo-L-alaninyl)-phosphorochloridate (0.28 g, 0.72 mmol). After column purification on silica gel **35** was obtained as an off-white solid (0.038 g, 17%). ^{31}P NMR (202 MHz, MeOD): δ_{P} 3.92, 3.78; ^1H NMR (500 MHz, MeOD): δ_{H} 8.04 – 8.0 (1H, m, *H*-Ar), 7.73 – 7.70 (1H, m, *H*-Ar), 7.53 (1H, apparent d, $J = 8.0$ Hz, *H*-Ar), 7.39 – 7.33 (3H, m, *H*-Ar), 7.27 – 7.23 (1H, m, *H*-Ar), 5.33, 5.31 (1H, 2 x d, $J = 3.0$ Hz, *H*-1'), 4.58, 4.55 (1H, 2 x dd, $J = 6.5, 3.0$ Hz, *H*-2'), 4.35 – 4.24 (2H, m, *H*-3', 1 x *H*-5'), 4.19 – 4.13 (1H, m, 1 x *H*-5'), 3.94 – 3.86 (2H, m, NHCHCH_3 , *H*-4'), 3.63 – 3.50 (2H, m, $\text{CH}_2\text{C}(\text{CH}_3)_3$), 2.15, 2.14 (3H, 2 x d, $J = 4.0$ Hz, CH_3), 1.22, 1.18 (3H, 2 x dd, $J = 7.0, 0.5$ Hz, NHCHCH_3), 0.75, 0.73 (9H, 2 x s, $\text{CH}_2\text{C}(\text{CH}_3)_3$); ^{13}C NMR (125 MHz, MeOD): δ_{C} 175.01, 174.87 (2 x d, $^3J_{\text{C-P}} = 5.3$ Hz, C=O , ester), 158.83, 158.79 (2 x d,

$^2J_{C-F}$ = 28.3 Hz, C-4), 150.55, 150.42 (C-2), 148.12, 148.07 (2 x d, $^2J_{C-P}$ = 5.2 Hz, O-C-Ar), 140.58, 140.54 (C-Ar), 139.92, 139.90 (2 x d, $^2J_{C-F}$ = 24.4 Hz, C-6), 139.35 (C-Ar), 137.54, 137.52 (2 x d, $^1J_{C-F}$ = 310.0 Hz, C-5), 128.85, 128.79, 127.75, 127.72, 127.41, 126.56, 126.52, 125.86, 122.95, 122.77 (CH-Ar), 116.35, 116.20 (2 x d, $^3J_{C-P}$ = 2.8 Hz CH-Ar), 94.65, 94.51 (C-1'), 83.71, 83.45 (2 x d, $^3J_{C-P}$ = 7.3 Hz, C-4'), 75.45, 75.35 (CH₂C(CH₃)₃), 73.21, 73.03 (C-2'), 71.18, 70.76 (C-3'), 68.66, 67.90 (2 x d, $^2J_{C-P}$ = 5.8 Hz, C-5'), 51.68 (NHCHCH₃), 32.31 (CH₂C(CH₃)₃), 26.73 (CH₂C(CH₃)₃), 20.96, 20.79 (2 x d, $^3J_{C-P}$ = 5.6 Hz, NHCHCH₃), 11.96 (d, $^3J_{C-F}$ = 3.4 Hz, C-6-CH₃); MS (ES+) m/z : 646.2 (M + Na⁺, 80%), Accurate mass: C₂₈H₃₅FN₃O₁₀P required 623.56 found 646.2 (M + Na⁺), 1269 (2 x M + Na⁺); Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, two peaks for two diastereoisomers with t_R = 17.72, 17.92 min.

5-Fluoro-6-methyluridine-5'-O-[1-naphthyl-(benzoxy-L-alaninyl)] phosphate

(36). Prepared according to the general procedure from 5-fluoro-6-methyluridine **7** (0.18 g, 0.65 mmol), NMI (0.26 mL, 3.26 mmol), 1-naphthyl-(benzoxy-L-alaninyl)-phosphorochloridate (0.52 g, 1.30 mmol). After column purification on silica gel **36** was obtained as an off-white solid (0.033 g, 8%). ³¹P NMR (202 MHz, MeOD): δ_P 3.94, 3.75; ¹H NMR (500 MHz, MeOD): δ_H 8.13 – 8.09 (1H, m, *H*-Ar), 7.82 – 7.79 (1H, m, *H*-Ar), 7.62 (1H, apparent d, J = 8.5 Hz, *H*-Ar), 7.48 – 7.41 (3H, m, *H*-Ar), 7.35 – 7.29 (1H, m, *H*-Ar), 7.25 – 7.19 (5H, m, *H*-Ar), 5.41, 5.39 (1H, 2 x d, J = 3.0 Hz, *H*-1'), 5.02 – 4.93 (2H, m, CH₂Ph), 4.68, 4.65 (1H, 2 x dd, J = 6.5, 3.0 Hz, *H*-2'), 4.44 – 4.34 (2H, m, *H*-3', 1 x *H*-5'), 4.27 – 4.22 (1H, m, 1 x *H*-5'), 4.06 – 3.94 (2H, m, NHCHCH₃, *H*-4'), 2.21, 2.20 (3H, 2 x d, J = 4.0 Hz, CH₃), 1.28, 1.24 (3H, 2 x dd, J = 7.0, 1.0 Hz, NHCHCH₃); ¹³C NMR (125 MHz, MeOD): δ_C 173.39, 173.26 (2 x d, $^3J_{C-P}$ = 4.75 Hz, C=O, ester), 157.45, 157.40 (2 x d, $^2J_{C-F}$ = 26.0 Hz, C-4), 149.13, 149.02 (C-2), 146.65, 146.63 (2 x d, $^2J_{C-P}$ = 7.0 Hz, O-C-Ar), 139.15, 139.09 (C-Ar), 138.52, 138.46 (2 x d, $^2J_{C-F}$ = 24.0 Hz, C-6), 136.58, 135.53 (2 x d, $^1J_{C-F}$ = 192.4 Hz, C-5), 134.84 (d, $^3J_{C-P}$ = 1.6 Hz, C-Ar), 128.15, 128.10, 127.88, 127.81, 127.77, 127.42, 127.36, 126.33, 126.30, 126.02, 125.14, 125.10, 124.44, 121.56, 121.34 (CH-Ar), 115.01, 114.79 (2 x d, $^3J_{C-P}$ = 3.0 Hz CH-Ar), 93.20, 93.06 (C-1'), 82.25, 81.87 (2 x d, $^3J_{C-P}$ = 7.0 Hz, C-4'), 71.75, 71.30 (C-2'), 69.75, 69.20 (C-3'), 67.19 (d, $^2J_{C-P}$ = 5.8 Hz, C-5'), 66.58, 66.44 (OCH₂), 66.23 (d, $^2J_{C-P}$ = 5.8 Hz, C-5'), 50.25 (d, $^3J_{C-P}$ = 5.3 Hz, NHCHCH₃), 19.21, 19.16 (2 x d, $^3J_{C-P}$ = 6.3 Hz, NHCHCH₃), 10.53 (d, $^3J_{C-F}$ =

3.6 Hz, C-6-CH₃); MS (ES+) m/z : 687.58 (M + Na⁺, 10%), Accurate mass: C₃₀H₃₁FN₃O₁₀P required 643.55 found 666.2 (M + Na⁺), 1309.4 (2 x M + Na⁺), Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, two peaks for two diastereoisomers with t_R = 16.89, 17.15 min.

5-Fluoro-6-ethyluridine-5'-O-[1-naphthyl-(benzoxy-L-alaninyl)] phosphate (37).

Prepared according to the general procedure from 5-fluoro-6-ethyluridine **8** (0.15 g, 0.52 mmol), NMI (0.21 mL, 2.58 mmol), 1-naphthyl-(benzoxy-L-alaninyl)-phosphorochloridate (0.42 g, 1.03 mmol). After column purification on silica gel **37** was obtained as an off-white solid (0.027 g, 8%). ³¹P NMR (202 MHz, MeOD): δ_P 3.88, 3.73; ¹H NMR (500 MHz, MeOD): δ_H 8.19 – 8.15 (1H, m, *H*-Ar), 7.88 – 7.87 (1H, m, *H*-Ar), 7.68 (1H, dd, J = 8.5, 1.0 Hz, *H*-Ar), 7.55 – 7.47 (3H, m, *H*-Ar), 7.42 – 7.35 (1H, m, *H*-Ar), 7.35 – 7.26 (5H, m, *H*-Ar), 5.45, 5.43 (1H, 2 x d, J = 3.0 Hz, *H*-1'), 5.08 – 4.98 (2H, m, CH₂Ph), 4.75, 4.70 (1H, 2 x dd, J = 6.5, 3.0 Hz, *H*-2'), 4.51 – 4.39 (2H, m, *H*-3', 1 x *H*-5'), 4.37 – 4.28 (1H, m, 1 x *H*-5'), 4.12 – 4.01 (2H, m, NHCHCH₃, *H*-4'), 2.83 – 2.65 (2H, m, CH₂CH₃), 1.36 – 1.24 (6H, m, NHCHCH₃, CH₂CH₃); ¹³C NMR (125 MHz, MeOD): δ_C 174.80, 174.66 (2 x d, ³ J_{C-P} = 3.75 Hz, C=O, ester), 159.0 (d, ² J_{C-F} = 27.5 Hz, C-4), 150.71, 150.61 (C-2), 148.07 (d, ² J_{C-P} = 6.25 Hz, O-C-Ar), 139.90 (C-Ar), 138.13 (d, ² J_{C-F} = 24.0 Hz, C-6), 136.26 (d, ¹ J_{C-F} = 220.5 Hz, C-5), 130.77 (C-Ar), 129.57, 129.53, 129.23, 128.85, 128.78, 128.29, 127.89, 127.74, 127.72, 127.44, 126.57, 126.54, 126.53, 125.88, 122.99, 122.77, 121.91 (CH-Ar), 116.44, 116.27 (2 x d, ³ J_{C-P} = 2.5 Hz CH-Ar), 94.65, 94.53 (C-1'), 83.87, 81.72 (2 x d, ³ J_{C-P} = 7.0 Hz, C-4'), 71.64, 71.31 (C-2'), 68.71, 68.02 (C-3'), 67.84 (d, ² J_{C-P} = 7.5 Hz, C-5'), 65.27 (OCH₂Ph), 51.65 (d, ³ J_{C-P} = 6.5 Hz, NHCHCH₃), 20.68, 20.58 (2 x d, ³ J_{C-P} = 6.3 Hz, NHCHCH₃), 19.64 (C-6-CH₂CH₃), 12.74, 12.65 (C-6-CH₃); MS (ES+) m/z : 680.2 (M + Na⁺, 100%), Accurate mass: C₃₁H₃₃FN₃O₁₀P required 657.58 found 680.2 (M + Na⁺), 1337.4 (2 x M + Na⁺), Reverse-phase HPLC, eluting with H₂O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min, λ = 254, two peaks for two diastereoisomers with t_R = 18.60, 18.77 min.

Molecular Modelling

All molecular modelling studies were performed on a Viglen Genie Intel®Core™ i7-3770 vPro CPU@ 3.40 GHz x 8 running Ubuntu 14.04. Molecular Operating Environment (MOE) 2015.10⁴⁶ and PLANTS⁴⁷ were used as molecular modelling

software. The human HINT-1 structure was downloaded from the PDB data bank (<http://www.rcsb.org/>; PDB code 1KPF). Hydrogen atoms were added to the protein, using the Protonate 3D routine of the Molecular Operating Environment (MOE). Ligand structures were built with MOE and minimized using the MMFF94x force field until a RMSD gradient of $0.05 \text{ kcal mol}^{-1}/\text{\AA}^{-1}$ was reached. The docking simulations were performed using PLANTS applying the following parameters: search algorithm: aco_ants 20, aco_evap 0.15, aco_sigma 2.0; binding site: bindingsite_center [10.77 11.16 13.79], binding site_radius 12; cluster algorithm: cluster_rmsd 2.0, cluster_structures 10; scoring function: chemplp. The reliability of PLANTS docking results has been validated by docking the AMP substrate into HINT-1 catalytic site and then measuring the root mean square deviation (RMSD) of the best docking pose obtained with the co-crystallized AMP giving a RMSD value of 1.0180.

ACKNOWLEDGMENT

The authors thank Su Kee Ngan for excellent laboratory assistance and NuCana (MS) for funding the research work described in this paper. A.B. and S.F. acknowledge the support of the Life Science Research Network Wales grant no. NRNPGSep14008, an initiative funded through the Welsh Government's Sêr Cymru program. The authors are grateful to Professor Jan Balzarini for valuable and helpful discussions.

Reference:

1. Robins RK. The potential of nucleoside analogs as inhibitors of retroviruses and tumors. *Pharm Res*. 1984;1:11–18.
2. De Clercq E. Antiviral drugs in current clinical use. *J Clin Virol*. 2004;30:115–133.
3. Jordheim LP, Durantel D, Zoulim F, et al. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. *Nature Reviews* 2013;12:447–464.
4. Kolberg M, Strand KR, Graff P, et al. Structure, function and mechanism of ribonucleotide reductases. *Biochemica et Biophysica Acta* 2004;1699:1–34.
5. Ju J, Pedersen-Lane J, Maley F, et al. Regulation of p53 expression by thymidylate synthase. *Proc Natl Acad Sci. USA*. 1999;96:3769–3774.
6. (a) Wu N, Mo Y, Gao J, Pai EF. Electrostatic stress in catalysis: Structure and mechanism of the enzyme orotidine monophosphate decarboxylase. *PNAS* 97;2000: 2017–2022. (b) Wittmann JG, Heinrich D, Gasow K, et al. Structures of the human orotidine-5'-monophosphate decarboxylase support a covalent mechanism and provide a framework for drug design. *Structure* 2008;16:82–92.
7. Lewis M, Meza-Avina ME, Wei L, et al. Novel interactions of fluorinated nucleotide derivatives targeting orotidine-5'-monophosphate decarboxylase. *J Med Chem*. 2011;54:2891-2901.
8. Poduch E, Bello AM, Tang S, et al. Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics. *J Med Chem*. 2006;49:4937–4945.
9. Meza-Avina ME, Wei U, Buhendwa MG, et al. Inhibition of orotidine 5'-monophosphate decarboxylase and its therapeutic potential. *Mini-Rev Med Chem*. 2008;8:239–247.
10. Bello AM, Poduch E, Liu Y, et al. Structure-activity relationships of C6-uridine derivatives targeting *plasmodia* orotidine monophosphate decarboxylase. *J Med Chem*. 2008;51:439–448.
11. (a) Radziecka A, Wolfenden R. A proficient enzyme. *Science* 1995;267:90–93; (b) Jordan F, Patel H. Catalysis in enzymatic decarboxylations: comparison of selected cofactor-dependent and cofactor-independent examples. *ACS Catal* 2013;3:1601–1617.

12. (a) Donovan WP, Kushner SR. Purification and characterization of orotidine-5'-monophosphate decarboxylase from *Escherichia coli* K-12. *J Bacteriol.* 1983;156:620–624; (b) Pragobpol S, Gero AM, Lee CS, et al. Orotate phosphoribosyltransferase and orotidylate decarboxylase from *Crithidia luciliae*: subcellular location of the enzymes and a study of substrate channeling. *Arch Biochem Biophys.* 1984;230:285–296.
13. Mundra S, Kotra LP. Design of inhibitors of ODCase. *Future Med Chem.* 2014;6:165–177.
14. (a) Rada B, Dragún M. Antiviral action and selectivity of 6-azauridine. *Ann. N. Y. Acad Sci.* 1977;284:410–417. (b) Chen JJ, Jones ME. Effect of 6-azauridine on the novo pyrimidine biosynthesis in cultured Ehrlich ascites cells. Orotate inhibition of dihydroorotase and dihydroorotate dehydrogenase. *J Biol Chem.* 1979;254:4908–4914; (c) Gabrielsen B, Kirsi JJ, Kwong CD, et al. In vitro and in vivo antiviral (RNA) evaluation of orotidine 5'-monophosphate decarboxylase inhibitors and analogues including 6-azauridine-5'-(ethylmethoxyalaninyl)phosphate (a 5'-monophosphate prodrug). *Antivir Chem and Chemother.* 1994;5:209–220.
15. Dix DE, Lehman CP, Jakubowski A, et al. Pyrazofurin metabolism, enzyme inhibition, and resistance in L5178Y cells. *Cancer Research* 1979;39:4485–4490.
16. Bello AM, Konforte D, Poduch E, et al. Structure-activity relationship of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents. *J Med Chem.* 2009;52:1648–1658.
17. Purohit MK, Poduch E, Wei LW, et al. Novel cytidine-based orotidine-5'-monophosphate decarboxylase inhibitors with an unusual twist. *J Med Chem.* 2012; 55:9988–9997.
18. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. *Leukemia* 2001;15:875–890.
19. Wagner CR, Iyer VV, McIntee EJ. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. *Med. Res. Rev.* 2000;20:417–451.
20. Pradere U, Garnier-Amblard EC, Coats SJ, et al. Synthesis of nucleoside phosphate and phosphonate prodrugs. *Chem Rev.* 2014;114:9154–9218.
21. Wiemer A, Wiemer DF. Prodrugs of phosphonates and phosphates: crossing the membrane barrier. *Top Curr Chem.* 2015;360:115–160.
22. Cahard D, McGuigan C, Balzarini J. Aryloxy phosphoramidate triesters as

protides. *Mini-Rev in Med Chem.* 2004;4:371–381.

23. Bhatia HK, Singh H, Grewal N, et al. Sofosbuvir: A novel treatment option for chronic hepatitis C infection. *J. Pharmacol Pharmacother.* 2014;5:278–282.

24. Cahn P, Rolon MJ, Gun AM, et al. Preclinical and first in human phase I clinical evaluation of stampidine, a potent anti-HIV pharmaceutical drug candidate. *J AIDS Clinic Res.* 2012;3:1000138.

25. NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
<https://clinicaltrials.gov/ct2/show/NCT00031616>.

26. Blagden S, Suppiah P, O'Shea D, et al. Final results from the first in human Phase I/II study of NUC-1031 in patients with solid tumours. ASCO Annual Meeting (2015) Poster, Abstract No: 2514.

27. Blagden SP, Slusarczyk M, Serpi M, et al. First in human Phase I study of NUC-3373, a nucleotide analogue designed to overcome fluoropyrimidine drug resistance mechanisms. Abstract CT028 Poster AACR (2016).

28. Balzarini J, Karlsson A, Aquaro A, et al. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. *Proc. Natl. Acad. Sci. USA.* 1996;93:7295–7299.

29. McGuigan C, Harris SA, Daluge SM, et al. Application of Phosphoramidate Pronucleotide Technology to Abacavir Leads to a Significant Enhancement of Antiviral Potency. *J Med Chem.* 2005;48:3504–3515.

30. McGuigan C, Madela K, Aljarah M, et al. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. *Bioorg Med Chem Lett.* 2010; 20:4850–4854.

31. McGuigan C, Murziani P, Slusarczyk M. et al. Phosphoramidate ProTides of anti-cancer agent FUDR successfully deliver the pre-formed bioactive monophosphate in cells and confer advantage over the parent nucleoside. *J Med Chem.* 2011;54:7247–7258.

32. Slusarczyk M, Huerta Lopez M, Balzarini J, et al. Application of ProTide technology to gemcitabine: A successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. *J Med Chem.* 2014;57:1531–1542.

33. Vande Voorde J, Liekens S, McGuigan C, et al. The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes. *Biochem Pharmacol.* 2011;82:441–452.
34. Andrei G, De Clercq E. Molecular approaches for the treatment of hemorrhagic fever virus infections. *Antiviral Res.* 1993;22:45–75.
35. (a) Briolant S, Garin D, Scaramozzino N, et al. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon- α and ribavirin combination. *Antiviral Res.* 2004;61:111–117; (b) Kaur P, Chu JJH. Chikungunya virus: an update on antiviral development and challenges, *Drug Discovery Today* 2013;18:969–983.
36. Pohjala L, Utt A, Varjak M, et al. Inhibitors of Alphavirus entry and replication identified with a stable chikungunya replicon cell line and virus-base assays. *PLOS ONE.* 2011;6:e28923.
37. (a) Singh KhD, Kirubakaran P, Nagarajan S, et al. Homology modelling, molecular dynamics, e-pharmacophore mapping and docking study of chikungunya virus nsP2 protease. *J Mol Model* 2012;18:39–51. (b) Bassetto M, De Burghgraeve T, Delang L, et al. Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus. *Antiviral Res.* 2013;98:12–18. (c) Rashad AA, Mahalingam S, Keller PA. Chikungunya virus: emerging targets and new opportunities for medicinal chemistry. *J Med Chem.* 2014;57:1147–1166.
38. Saboulard D, Naesens L, Cahard D, et al. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine. *Mol Pharmacol.* 1999;56:693–704.
39. Congiatu C, Brancale A, McGuigan C. Molecular modelling studies on the binding of some protides to the putative human phosphoramidase Hint1. *Nucleos Nucleot Nucl.* 2007;26:1121–1124.
40. Birkus G, Wang R, Liu X, et al. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. *Antimicrob Agents Chemother.* 2007;51:543–550.

41. Brenner C. Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferase. *Biochemistry* 2002;41:9003–9014.
42. Lima CD, Klein MG, Hendrickson WA. Structure-based analysis of catalysis and substrate definition in the HIT protein family. *Science* 1997;278:286–290.
43. Ozga M, Dolot R, Janicka M, et al. Histidine triad nucleotide-binding protein 1 (HINT-1) phosphoramidase transforms nucleoside 5'-O-phosphorothioates to nucleoside 5'-O-phosphates. *J Biol Chem*. 2010; 285:40809–40818.
44. Chou TF, Baraniak J, Kaczmarek R, et al. Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and *Escherichia coli* histidine triad nucleotide binding proteins. *Molecular Pharmaceutics* 2006;4:208–217.
45. ^{31}P and ^1H NMR analyses of phosphorochloridates are available in the supporting information <http://pubs.acs.org/doi/suppl/10.1021/jm401853a>
46. Molecular Operating Environment (MOE 2015.10); Chemical Computing Group, Inc.: Montreal, Quebec, Canada; URL <http://www.chemcomp.com> (2015).
47. Korb O, Stützle T, Exner T.E. PLANTS: Application of ant colony optimization to structure-based drug design. In: Ant Colony Optimization and Swarm Intelligence, 5th International Workshop, ANTS. Brussels, Belgium, Springer Berlin Heidelberg, 2006, 245–258, September 4–7.